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ABSTRACT

Follicle stimulating hormone (FSH) and luteinizing hormone (LH) are
glycoprotein gonadotropins from the anterior pituitary gland that are involved in
reproductive functions. They are heterodimeric proteins that share a common α-subunit
that is highly conserved amongst mammalian species, and is also conserved across this
family of proteins. The β-subunit confers receptor specificity and is distinct.
Recombinant gonadotropin expression would be an important advance for the bovine
superovulation industry, as there are a number of disadvantages associated with the
currently used pituitary-derived gonadotropins. For example, these pituitary products are
contaminated with other proteins including hormones, exhibit batch-to-batch
inconsistencies, and harbor the potential to spread disease-causing agents. Recombinant
preparations can overcome these negative issues because they are potentially free of
contaminating proteins. Further, recombinant gonadotropins can be produced so they
have no potential to transmit harmful agents.
Here, two heterologous systems, bacteria and yeast, have been surveyed for their
utility in the production of recombinant bovine FSH and LH (bFSH and bLH,
respectively). bFSH was tested using a rat ovarian weight gain assay to determine
biological activity and preliminary results indicate that the bacterial-derived bFSH had
activity. The activity of yeast-derived bFSH could not be determined as a result of
complications with the rat assay.
bLH was assayed using bovine granulosa cells treated in vitro with LH for one
day, followed by gene transcript profile analysis to characterize receptor binding and
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activation. Both recombinant preparations reduced expression of FSH receptor transcript
levels similar to pituitary LH, as expected. Both the pituitary LH and yeast LH decreased
transcript expression of LH receptor by 7.0-fold and 2.9 fold (respectively), suggesting an
autocrine down-regulatory effect. Notably, the bacterial preparation failed to yield
similar results (1.2-fold decrease), potentially because of the differences in posttranslational modifications that have been suggested to be important for protein
bioactivity.
Recombinant bLH was also used in a rat ovarian ascorbic acid depletion bioassay
to determine the impact of the compound at the whole animal level. Preliminary data
suggests there was an ovarian ascorbic acid increase with both pituitary and recombinant
LH treatments, rather than the expected decrease. Interestingly, the vehicle control
caused an ascorbic acid increase for unknown reasons. While both the bacterial bLH and
yeast bLH treatments resulted in an overall increase in relative ascorbic acid content postLH treatment, the concentrations were less than the vehicle-only control, suggesting an
overall reduction possibly as a result of activity maintained by the recombinant protein.
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CHAPTER ONE
LITERATURE REVIEW
(portions of this section are published in Reproduction in Domestic Animals, ePub March
2011)
Recombinant Gonadotropin Production
Recombinant proteins are produced from a heterologous host using molecular
cloning techniques. Recombinant protein production and usage first became
industrialized with the production of human insulin from a bacterial host in the early
1980s for control of human Type I diabetes (Johnson 1983). Unlike gonadotropins,
insulin is not post-translationally glycosylated, making heterologous expression in
bacteria relatively straightforward. Following insulin, a myriad of recombinant proteins,
including recombinant gonadotropins, have been produced, but high quality and
inexpensive recombinant hormone production remains challenging in part due to protein
glycosylations.
Initially, recombinant gonadotropins such as follicle stimulating hormone (FSH)
were produced as two separate subunits oligomerized after synthesis (Kaetzel et al. 1985;
Keene et al. 1989). Later efforts included studies aimed at the expression of constructs
that yielded both protein subunits fused together, which quickly became the standard
production method because it required fewer steps during synthesis and purification
(Olijve et al. 1996; D'Antonio et al. 1999).
The next focus of recombinant gonadotropin research included efforts to modify
the subunits to yield increased in vivo biological half-life (and therefore decrease the
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number of doses required for adequate superovulation). By engineering up to four extra
N-linked glycosylation consensus sites into the α-subunit (fused to the β-subunit),
retention time was enhanced (Perlman et al. 2003; Trousdale et al. 2009). Increased
retention time has also been achieved by adding a section of DNA that codes for a highly
glycosylated protein to one terminus of the protein; the most common of these being the
carboxy-terminal peptide (CTP) of human chorionic gonadotropin (hCG). The CTP has
been shown to cause a ~ 4-10-fold increase in biological half life in humans (Fares et al.
1992; Devroey et al. 2004; Fauser et al. 2009). The chimeric recombinant human FSH
(hFSH-CTP) facilitated follicular maturation 50 hours after the initial dose, comparable
to four injections of pituitary-derived hFSH delivered 12 hours apart (Fauser et al. 2009).
The increased retention time may be due to the extra negatively charged sialic acid
residues incorporated into the O-linked glycosylations within the CTP molecule. Acidic
residues tend to have reduced glomerular filtration in the kidney and a protective effect
within the liver (Fares et al. 1992; D’Antonio et al. 1999; Fauser et al. 2009). Further,
Matzuk et al. (1990) demonstrated that the biological activity of hCG was severely
impaired with the removal of the CTP region. Garcia-Campayo et al. (1997) extended
the biological activity of human luteinizing hormone (hLH) by the addition of the CTP
region.
More recently, researchers have developed fused α and β constructs that have the
ability to bind to multiple gonadotropin receptors (Figure 1.1, adapted from GarciaCampayo and Boime 2001). This has been accomplished by incorporating different βsubunits within the same construct, such as FSHβ and hCGβ. These “dual activity”
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Figure 1.1 “Dual activity” gonadotropins. Both LH and FSH β-subunits can be fused to the
common α-subunit. Association between the α-subunit and each individual β-subunit will occur
and form a blend of functional FSH and LH proteins. These proteins will bind and activate either
the FSHR and or the LHR.

gonadotropins have exhibited in vitro binding capacity to both FSH and LH receptors
(Kanda et al. 1999; Garcia-Campayo and Boime 2001; Garcia-Campayo et al. 2004;
Jablonka-Shariff et al. 2006), although variations in binding have been noted based on βsubunit orientation (Garcia-Campayo and Boime 2001). In sheep, an increase in estradiol
production as a result of treatment with a dual active FSH/LH gonadotropin was similar
to a combination of individual FSH and hCG hormones, suggesting the ability of the dual
gonadotropin was sufficient to activate both receptors and elicit multiple biological
responses (Adams and Boime 2008). The ability to produce a single hormone that has
both FSH and LH activity would simplify superovulation protocols and reduce costs
associated with labor. The optimal FSH:LH ratio during the follicular growth phase
associated with superovulation is unclear (Donaldson and Ward 1986; Takagi et al. 2001;
Kanitz et al. 2002), and, in human fertility, can be patient-dependent with factors such as
age, parity, and overall ovarian function impacting results (Agostinetto 2009). Supplying
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a dual-active gonadotropin may alleviate some of the problems encountered with
administering only FSH and allow the desired ratio of FSH:LH to be achieved using one
molecule. Further, the technology can be tweaked to include other gene domains such as
angiogenic or steroidogenic factors (Adams and Boime 2008).
Production methods
The most common recombinant protein production method for hFSH is
heterologous expression in Chinese hamster ovary (CHO) cells, a mammalian cell line
that is capable of providing native post-translational modifications to nascent proteins.
These cells can secrete the hormone into the culture media, from which it is purified and
analyzed for activity. Despite the fact that CHO cell cultures are able to produce proteins
almost identical to their endogenous structure, these cells are cultured in vitro using fetal
bovine serum (FBS), which could potentially harbor disease-transmissible materials. The
FBS that is routinely used in commercial production of recombinant gonadotropins is
collected from countries that are free of prion diseases (to date) such as bovine
spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD).
However, it can sometimes take years for symptoms to appear which makes this a fluid
classification (Balen 2002). CHO cells do not flourish properly in the absence of FBS,
which makes harvesting adequate supplies of recombinant proteins from them difficult.
Recently, recombinant gonadotropin production from modified CHO cells has been
conducted in the absence of FBS, resulting in proteins that exhibit similar biological
activity to previous products produced in the presence of FBS (Kim et al. 2010).
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Similar to hFSH, bovine (bFSH) was initially produced in CHO cells and found to
have biological activity (Looney et al. 1988; Wilson et al. 1993), but is no longer
available in sufficient quantities for commercial purposes. Other production methods
have been explored for both FSH and LH and have resulted in a biologically active
protein. However, none have proven superior to CHO cell production (except for not
requiring FBS for cell culture). These methods employ the use of bacteria (Wilson
2009), viruses (Chappel et al. 1988), insects (van de Wiel et al. 1998; Ko et al. 2007;
Zmora et al. 2007; Kazeto et al. 2008), tobacco plants (Dirnberger et al. 2001), yeast
(Richard et al. 1998; Gadkari et al. 2003; Fidler et al. 2003; Kasuto and Levavi-Sivan
2005), and transgenic milk (Galet et al. 2001; Coulibaly et al. 2002). The use of hosts
such as bacteria and yeast may provide a safer alternative to CHO production due to the
lack of FBS utilization. Conversely, these systems do not harbor the glycosylation
capabilities employed by CHO cells, and in some cases hyperglycosylate proteins, which
may or may not have positive effects on biological activity (Porro et al. 2005). A
chronological summary of the history of recombinant FSH and LH protein production
schemes can be found in Tables 1.1 and 1.2, respectively. These tables highlight the
progression of recombinant gonadotropin production, as well as give insight into the
protein construction and resulting activity of each construct.
Delivery methods
In parallel with the quest for recombinant gonadotropins exhibiting longer in vivo
biological half-life is an improved delivery method that would require fewer injections.
Much research has been devoted to identifying an adjuvant that, when mixed with the
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Table 1.1 Chronological history of recombinant FSH1 produced in heterologous systems.
Production
Species
In vitro activity
In vivo activity
System
a
Bovine
BPV
Progesterone in granulosa cells
Activity in SP Assay
CHO cellsa
NR
Increased embryos in cattle
Human
CHO cellsa
Aromatase in rat granulosa cells
NR
Human
CHO cellsf
Estrogen in granulosa cells
Increased FSH activity with CTP
Bovine
CHO cellsa
NR
Increased embryos in cattle
Human
CHO cellsb
pI and isoform heterogeneity like
NR
native
Porcine
Insecta
Estrogen in Sertoli cell assay
Mouse uterine weight assay
Rat
CHO cellsb
Active in Sertoli and granulosa cells
Activity in SP Assay
cAMP
NR
Bovine
Baculovirusa
Ovine
Yeastc
cAMP from CHO cells
NR
Progesterone in granulosa cells
NR
Porcine
Insecta
cAMP in CHO cells; progesterone
NR
Yeastc
in Y1 adrenal cells
Human
CHO cellsa
Y1 adrenal and CHO cells
Activity in SP Assay
stimulated
Bovine
Tobacco plantc
cAMP in CHO cells
Increased oocytes
Human
CHO cells
NR
Stimulated follicles in cattle
Bovine
Rabbit milkb
Luciferase in CHO cells
NR
c
Ovine
Yeast
cAMP from CHO cells
NR
Human
NR
NR
Human IVF
Channel
Drosophilaa
cAMP in COS cells; steroidogenesis
NR
catfish
in ovarian and testicular cells
cAMP production by CHO cells
NR
Human
Transgenic
micec
Manchurian
Silkwormc
cAMP from COS cells
Increased follicular diameter in
trout
female adult trout ovary
Human
CHO cellsd
NR
Increased estrogen production in
sheep
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Reference
Chappel et al. 1988
Looney et al. 1988
Keene et al. 1989
Fares et al. 1992
Wilson et al. 1993
Olijve et al. 1996
Inaba et al. 1997
Hakola et al. 1997b
Van de Wiel et al. 1998
Fidler et al. 1998
Kato et al. 1998
Richard et al. 1998
D’Antonio et al. 1999
Dirnberger et al. 2001
Takagi et al. 2001
Coulibaly et al. 2002
Fidler et al. 2003
Devroey et al. 2004
Zmora et al. 2007
Kim et al. 2007
Ko et al. 2007
Lemke et al. 2008

Species
Japanese
eel
Bovine
Equine

Production
System
Drosophilaa

In vitro activity

In vivo activity

Reference

cAMP production by COS cells

Failed to stimulate gonadal growth
Kazeto et al. 2008
in immature male eels
Bacteriac
NR
Activity in SP Assay
Wilson 2009
CHO cellsd
NR
Increased total number of follicles
Jennings et al. 2009
CHO cellsb
cAMP in CHO cells
Activity in SP Assay
Fachal et al. 2010
Human
CHO cellsg
NR
Hyperglycosylation increased
Trousdale et al. 2009
fertility rates
Japanese
Silkwormd
Eel oocyte maturation
Induced spermatogenesis in
Kobayashi et al. 2010
immature eels
eel
1
Abbreviations: FSH: follicle stimulating hormone, BPV: Bovine Papilloma Virus, SP: Steelman-Pohley assay, NR: not reported, cAMP:
cyclic adenosine monophosphate, CHO: Chinese hamster ovary, CTP: carboxy terminal peptide. aIndividual subunits assembled postproduction, bfused protein α/β orientation, cfused protein β/α orientation, dfused protein β-CTP-α, efused protein α-CTP-β, findividual
subunits assembled post-production with β-CTP, gFSH construct hyperglycosylated.
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Table 1.2 Chronological history of recombinant LH1 produced in heterologous systems.
Production
Species
In vitro activity
In vivo activity
System
a
Bovine
CHO cells
Increased progesterone in ovine luteal
NR
cells
Rat
CHO cellsb
Increase cAMP in mouse Leydig cells
No seminal vesicle increase in rats
Equine
Rabbit milkc
Increased testosterone in rat Leydig
No significant ovarian weight
cells
increase when compared to
controls
Human
Yeasta
Increased progesterone in Leydig cells
NR
a
Equine
Insect
Increased progesterone in Y1 adrenal
No effect on ovary growth of rats
cells
Tilapia
Yeastc
Increased testosterone in tilapia testes
NR
Channel
catfish

Drosophilaa

Equine

CHO cellsc

Manchurian
trout
Bovine

Silkwormc
CHO cellsde

Japanese Eel

Drosophilaa

Stimulated cAMP in COS cells;
induced steroidogenesis in ovarian and
testicular cells
Increased testosterone in equine Leydig
cells
cAMP increased in COS cells
Increased progesterone in rat granulosa
cells and bovine theca cells (α-CTP-β.>
β-CTP-α)
cAMP increased in COS cells

NR

Increased LH and testosterone in
stallions
No effects on female adult trout
ovary
NR

Reference
Kaetzel et al. 1985
Hakola et al. 1997a
Galet et al. 2001
Gadkari et al. 2003
Legardinier et al. 2005
Kasuto and LevaviSivan 2005
Zmora et al. 2007

Jablonka-Shariff et al.
2007
Ko et al. 2007
Grinberg et al. 2008

Failed to stimulate gonadal growth
Kazeto et al. 2008
in immature male eels
Silkwormd
Induced eel oocyte maturation
Induced spermatogenesis in
Kobayashi et al. 2010
immature eels
1
Abbreviations: LH: luteinizing hormone, CHO: Chinese hamster ovary, NR: not reported, cAMP: cyclic adenosine monophosphate, CTP:

carboxy terminal peptide. aindividual subunits assembled post-production, bfused protein α/β orientation, cfused protein β/α orientation,
d

fused protein β-CTP-α, efused protein α-CTP-β.
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gonadotropin, would allow a slow release of FSH over time to induce a superovulatory
response similar to multiple traditional injections (Takedomi et al. 1995; Satoh et al.
1996). Looney et al. (1981) injected cattle once a day with FSH embedded within gelatin
and found the single injection per day resulted in more corpora lutea and viable embryos
when compared to the standard protocol of twice a day injections. FSH is rapidly cleared
from circulation, being undetectable in plasma 12 hours after intra-muscular injection.
However, after intra-muscular injection of FSH dissolved in aluminum hydroxide gel into
cattle, FSH was detected in plasma up to 4 days post-injection, negating the need for
multiple injections (Kimura et al. 2007). In another study, Floyd (2007) tested the ability
of polyethylene glycol (PEG) or polyacrylamide to act as a slow-release implant for FSH
in vitro; results indicated both materials enhanced slow release of FSH over a 24 hour
period. Porcine FSH bound to PEG is competent in receptor activation in vitro and also
reduces immunological response without affecting bioactivity in vivo, but more studies
are necessary to determine the effect on half-life sustainability (Uchiyama et al. 2010).
Low et al. (2005) demonstrated that FSH bound to the Fc domain of IgG retained in vivo
activity after transport across gut epithelial cells, introducing the possibility for an oral
administration route. hFSH has also been administered through less frequent vaginal
subcutaneous injections which provoked an adequate superovulatory response while
using a minimal amount of hormone given with fewer required injections (Hsu et al.
2009).
Superovulation
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Superovulation is the manipulation of the endogenous FSH surge that gives rise to
a follicular wave that can be persuaded to produce multiple follicles capable of ovulating.
Superovulation, along with embryo transfer, is used to propagate superior genetics
horizontally within a single generation. Once multiple follicles have ovulated, the ova
can be fertilized with fresh or frozen semen and after 7 days, the embryos are collected
by non-surgically washing via uterine lavage, a technique called flushing. The embryos
are then transferred to recipient dams, a process termed embryo transfer.
Occurrence
Bovine superovulation is becoming more common, as indicated by the increasing
number of embryo collections and subsequent transferable embryos. The International
Embryo Society Data Retrieval Committee reported in 2007 over 122,000 bovine embryo
collections spanning 5 continents (52% of the total embryos transferred reported from
North America), resulting in almost 764,000 transferable embryos for an average of ~6
embryos/collection (Thibier 2008). This activity has nearly doubled in 10 years, from
~82,000 embryo collections and ~456,000 transferable embryos recorded in 1997,
however the average of ~6 embryos/collection has not changed. Worldwide, the use of
embryo transfer in other ruminant species (namely sheep, goats, and deer) has also
increased, with ~10,000 embryo collections in 1997 as compared to ~27,000 embryo
collections in 2008 (Thibier 1998; Thibier 2008). At the onset of superovulatory
protocols in the 1970s, >95% of all recovered embryos were collected within the dairy
industry and were transferred surgically. After non-surgical collection and transfer
techniques were developed, the use of superovulation expanded to the beef industry
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where it is currently responsible for ~70% of all the recovered embryos. Despite the
steady increase in occurrence of superovulation, transferable embryo recovery
efficiencies have been stagnant at ~6 recovered embryos per collection (Thibier 1998;
Hasler 2003; Thibier 2008).
Optimization of FSH use in superovulation
There have been many advances in the use of FSH in superovulatory protocols
where the desired outcome is to maximize the height and breadth of the endogenous FSH
curve to increase the number of follicles in several size categories as well as the number
of ovulations (Gibbons et al. 1997). Many aspects have been considered including the
timing of exogenous FSH delivery relative to follicular wave emergence (Adams et al.
1992; Nasser et al. 1993; Ginther et al. 1996), methods of FSH delivery (Looney et al.
1981; Murphy et al. 1998; Bo et al. 1994), location or route of delivery (Bo et al. 1994;
Mapletoft et al. 2002), and the purity of the FSH being delivered (Hill et al. 1984;
Donaldson and Ward 1986; Braileanu et al. 1998).
Ovarian follicles grow in waves (2 or 3 in the bovine estrous cycle) culminating in
one follicle gaining dominance and regression of the remaining follicles (Adams et al.
1992). A new follicular wave is initiated following the demise of the dominant follicle
(Ko et al. 1991; Adams et al. 1993). Destruction of the dominant follicle is a proven
method of initiating a new follicular wave and can be performed mechanically with
transvaginal ultrasound-guided follicular ablation (Bergfelt et al. 1994; Bodensteiner et
al. 1996; Bergfelt et al. 1997; Baracaldo et al. 2000). This may not be useful in a
commercial livestock setting due to high labor costs. Removal of the dominant follicle
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can also be achieved by various pharmaceutical treatments (Bo et al. 1994; Bo et al.
1996; Mapletoft et al. 2002; Bo et al. 2008).
Typical superovulatory protocol in cattle
A natural follicular wave (usually the second) is enhanced by initiation of FSH on
the day of or the day before the start of the new follicular wave when the largest follicles
of the new wave average ~4 mm, approximately day 10 following estrus. FSH is
delivered in a regimen of 8 total intramuscular injections, twice daily in decreasing doses
over 4 days (25-50 mg total protein delivered, dependent upon breed, parity, age, weight,
etc.). ProstaglandinF2α (25 mg/dose) is usually administered concomitant with the 5th
and 6th FSH injection, approximately 48 and 36 hours before expected estrus (Bo et al.
1995; Mapletoft et al. 2002). Cows are bred by artificial insemination at standing estrus
and 12 hours later. Seven days later, embryos are collected by non-surgical trans-cervical
uterine lavage, processed, graded, and transferred fresh or frozen for later use.
Challenges within the current bovine superovulation system
Bovine ovarian hyperstimulation is an essential step in the maintenance of high
quality genetics in the beef and dairy industries. Currently, bovine ovarian
hyperstimulation (or superovulation) requires pituitary-derived FSH, typically obtained
from porcine or ovine species, to stimulate multiple follicles to achieve dominance and
ovulatory capacity. In the past, products such as equine chorionic gonadotropin (eCG),
also known as pregnant mare serum gonadotropin (PMSG), have been used to stimulate
superovulation. The use of FSH has advantages over eCG that include a decrease in
follicular cysts and more consistent results; however, FSH has a shorter half-life than
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eCG (~1.5 h vs. ~120 h, respectively) requiring multiple injections to obtain results
similar to those found with eCG (Galli et al. 2003). Studies have shown FSH yields a
more consistent ovulatory response (Bellows and Short 1972; Elsden et al. 1978).
Further, the prolonged biological activity of eCG can negatively affect early embryonic
development, requiring the use of an anti-eCG injection to reduce activity (Boland et al.
1991). Irrespective of the gonadotropin choice, the most labor-intensive and costly part
of superovulation is the administration of gonadotropins. With increasing labor costs, the
embryo transfer industry will likely become stagnant without improvements (Hasler
2003).
Multiple factors have confounded efforts to standardize superovulatory protocols
in cattle. Superovulatory variation has been reported at a range of 0-60 recovered
embryos per donor, with 20% of donors producing no transferable embryos (Hasler
2003). Aged donors have been found to exhibit a lower follicular and ovulatory response
as a result of ovarian hyperstimulation (Malhi et al. 2008), and differences in breedspecific responsiveness have been debated (Donaldson 1984; Krininger et al. 2003). A
large source of variation comes from the individual farm, encompassing environmental
location, recipient and/or donor management, semen/embryo handling, and animal
nutrition schemes (Kafi and McGowan 1997; Yaakub et al. 1999; Stroud and Hasler
2006).
Another source of variation in superovulatory response may result from the
presence of a dominant follicle. Guilbault et al. (1991) reported a lower number of
corpora lutea and lower progesterone concentrations in heifers superovulated in the
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presence of a dominant follicle when compared to those without a dominant follicle,
suggesting a reduced superovulatory response. Other research supports these results,
finding an increased number of transferable embryos following follicular ablation (Kim
et al. 2001; Lima et al. 2007). Stock et al. (1996) found that when a dominant follicle
was present, follicular response to superovulation was not hindered, but fewer ovulations
occurred. Diaz et al. (2001) reported reduced follicular response in the presence of a
dominant follicle, but suggested exogenous FSH may compensate for any deleterious
effects resulting from the dominant follicle. In a conflicting study, no negative effects
were reported on superovulatory response of lactating dairy cows with a dominant follicle
(Maciel et al. 1995). All of these issues potentially contribute to bovine superovulatory
variability and lead to reduced embryo recovery rates, usually requiring specialization of
the protocol (Lerner et al. 1986).
Superovulatory response variability introduced by gonadotropins
One of the primary contributing factors to low embryo recoveries is the variability
introduced by pituitary-derived gonadotropins which suffer from the following
drawbacks: 1) potentially high FSH:LH ratios (Kafi and McGowan 1997; Galli et al.
2003; Adams and Boime 2008), 2) batch-to-batch inconsistencies (Murphy et al. 1984;
Kanitz et al. 2002; Galli et al. 2003), and 3) potential disease transmission (Galli et al.
2003; Adams and Boime 2008).
Variable LH activity within commercially-available pituitary-derived preparations
of FSH is a clear disadvantage to the use of these products. Failure to limit LH
contamination in FSH preparations reduces the percentage of transferable embryos and
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increases variability of successful transfers (Ward 1986; Kanitz et al. 2002). An
increased amount of LH early in the superovulatory protocol may activate the LH
receptor (LHR) leading to premature luteinization, resulting in early ovulation of the
follicles and ultimately leading to decreased fertilization rates and embryo production.
Further, the concentration of naturally-occurring isoforms of LH present within the FSH
preparation may interfere with the effectiveness of FSH. Kanitz et al. (2002)
demonstrated that LH was unnecessary for efficient superovulation and that a small
amount was tolerable to the protocol before it began to have a negative effect on
fertilization rates and the number of transferable embryos. Other researchers have
supported this hypothesis and suggest a “ceiling effect” occurs where limited
concentrations of LH can be tolerated during folliculogenesis before it manifests
deleterious effects (Loumaye 2002; Muasher et al. 2006; Gibreel and Bhattacharya 2010).
The number of recovered transferable embryos and the amount of LH detectable in FSH
preparations have an inverse relationship (Chupin et al. 1984; Donaldson and Ward 1986;
Donaldson et al. 1986; da Costa et al. 2001). Recent commercially available FSH
preparations contain a reduced amount of detectable LH activity (achieved through
biochemical purification methods), and increasing the dosage up to twofold above the
conventional pituitary-derived FSH dose for superovulation does not appear to affect
embryo quality (Gonzalez et al. 1990).
Studies have been performed to identify a range of acceptable LH contamination.
Willmott et al. (1990) suggests the acceptable maximum of detectable LH activity of an
FSH preparation to be between 15 and 20% before superovulatory response is hindered.
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Tribulo et al. (1991) reports a similar optimal LH amount (~16% of the preparation),
however seasonal affects on superovulatory response were noted. Seasonal affects were
also noted by Page et al. (1989), where LH contamination had no effect on
superovulation of Holstein heifers in cool months, but a small amount of LH was
preferable during the stressful heat of summer months. Takagi et al. (2001) demonstrated
that heifers superovulated with a recombinant hFSH preparation (no detectable LH) had
reduced follicular maturation, which they attributed to the lack of LH in the preparation.
The amount of LH in an FSH preparation may influence the dosages of FSH
required because the granulosa cells of the larger follicles are predominantly LHdependent, rather than relying solely on FSH to mature to ovulation (Adams et al. 1992).
This fact is crucial to our proposed working model, where low to no detectable LH is
included in the early FSH injections of superovulation, followed by an increasing
percentage of LH in the later stages, which may result in more ovulations, providing the
opportunity for increased fertilization (Figure 1.2). This could be accomplished by
combining pure, recombinant preparations of each protein in a fixed and controllable
ratio. Alper et al. (2008) reported that combining FSH and LH into one dose and treating
rats did not affect either of the proteins’ bioactivity. Unfortunately, the precise ratio of
FSH:LH at various times during superovulation is unknown, but recombinant protein
production is enabling technology to further define the role of each gonadotropin in the
endocrine-intrafollicular relationship during a superovulatory situation. Experimentation
with pure gonadotropins is necessary to elucidate these issues, and recombinant protein is
the most efficient way to manufacture preparations that are completely void of the

16

Figure 1.2 Working model for future superovulation regimen utilizing pure, recombinant
FSH and LH preparations and corresponding ovarian and follicular responses beginning on
day 10 of estrous cycle.
A: Relative doses of recombinant FSH and LH administered in a single injection during a typical
4 day dose regimen for superovulation (days 10-14 of estrous cycle). Superovulatory doses for
FSH begin at a high level (indicated by dark grey) and taper off to a low level (indicated by the
fade gradient ending in white). Doses for LH begin at a low level (indicated by white) at the
beginning of superovulation and increase throughout dosing regimen, ending at a high level to
induce ovulation of multiple follicles (indicated by gradient ending in dark grey). B: Cohort of
follicles maturing during superovulation. Deviation occurs when follicles reach ~10 mm,
approximately on Day 3 of superovulation. The follicles that fail to attain a diameter of ~10 mm
usually become atretic while the deviated follicles will go on to ovulation. C: GC of DF
predominantly express FSHR (7-pass transmembrane protein with dark grey bars) with a limited
amount of LHR (7-pass transmembrane protein with light grey bars) on their surface until
deviation, in which they alter expression to predominantly LHR to prepare for ovulation. D: GC
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of SF also predominantly express FSHR prior to deviation, however following deviation, they
become atretic and do not express significant quantities of FSHR or LHR, and the receptors that
may be present on the cell surface are inactivated due to the presence of the DF (*).
Abbreviations: SO: superovulation, E: estrus, OV: ovulation, rec: recombinant, FSH: follicle
stimulating hormone, LH: luteinizing hormone, GC: granulosa cell, DF: dominant follicle, SF:
subordinate follicle, FSHR: FSH receptor, LHR: LH receptor.

contaminating gonadotropin. Further, experimenting with the delivery method (minipump or implant, for example) of the gonadotropins, specifically LH, could alleviate
some of the disadvantages of using the product, namely premature ovulation of maturing
follicles resulting from the delivered bolus.
Because ~60 isoforms of FSH and LH are naturally produced within the pituitary
(based on phase of estrous cycle as well as age and parity), differences exist within and
among batches of pituitary extracts (Kanitz et al. 2002; Gibreel and Bhattacharya 2010).
Gonadotropin isoforms differ based on their degree of glycosylation, as well as the
specific carbohydrate moieties that are incorporated (Stanton et al. 1993; D'Antonio et al.
1999). Phillips et al. (1993) tested five pituitary preparations for in vitro activity and
metabolic clearance rates (using a rodent model), and found there were differences
among the batches for both assays. Kanitz et al. (2002) tested four pituitary batches of
FSH for bioactivity using a rat ovarian weight gain assay, followed by testing
superovulatory responses in cattle. Their findings showed a wide range of bioactivity and
the resulting number of transferable embryos differed among the preparations.
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A more recent concern is the potential for pituitary extracts to harbor infectious
agents, including prions, which may be passed to the recipient animal (Galli et al. 2003;
Adams and Boime 2008). Some European countries have banned the use of pituitaryderived gonadotropins in superovulation because of this risk, disabling the current
protocols and crippling the embryo transfer industry in those countries. One possible
solution is to use recombinant gonadotropins, which is well established for human in
vitro fertilization protocols (Galli et al. 2003).
Costs associated with superovulation
Currently, gonadotropins are the most expensive component of the superovulation
protocol, costing ~$100/superovulation to meet the requirements for FSH using a
pituitary-derived product. Introducing recombinant FSH into this protocol may not
substantially reduce cost, but the benefits of using a pituitary-free product (no pituitary
contaminants, no possibility for disease transmission, increased transferable embryo
recovery rates, etc.) would likely yield considerable benefits. The cost of producing
recombinant proteins from a small culture in a university setting can be as much as 3-5X
higher than that of the pituitary product; however, industrializing the production will
substantially reduce costs incurred due to culture media and labor, the primary
contributing factors to the expense.
Use of LH in synchronizing ovulation in cattle
A combination of progesterone and estrogen is the conventional follicular wave
synchronizing protocol which will initiate a follicular wave 4 days post-treatment (Bo et
al. 1995). Recently, research has focused on alternative synchronizing methods, such as
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follicular ablation, gonadotropin releasing hormone (GnRH), or LH. As previously
mentioned, follicular ablation may not be cost-effective in farm settings, as it requires
expensive technology that must be operated by skilled professionals (Bo et al. 2010).
GnRH is the conventional ovulatory stimulator in synchronization protocols (Pursley et
al. 1995), but has been shown to be less effective than pituitary LH at stimulating
ovulation (56% and 78%, respectively) in dairy heifers, however both products induced a
new follicular wave within 2 days post-treatment if that treatment resulted in ovulation
(Martinez et al. 1999). Ambrose et al. (2005) reported pregnancy rates of 59% when
synchronizing estrus with GnRH [combined with timed artificial insemination (AI)] as
compared to 46% with the use of pituitary LH, but also indicated an increase in
progesterone production after LH treatment. Further, the cost-effectiveness of LH as an
ovulatory stimulator (when compared to GnRH) is currently unknown (Ree et al. 2009).
A combination of the two products has shown more promising results than using two
treatments of GnRH in a timed AI scenario (Pursley et al. 1995; Colazo et al. 2009).
Neither GnRH nor LH have historically proven to elicit reliable and predictable
ovulations possibly due to efficacy differences during various stages of cyclicity leading
to premature ovulations in some animals (Martinez et al. 1999); thus, a carefully
characterized recombinant LH product may overcome these issues and allow for more
dependable ovulations and synchronizations.
Human infertility
Gonadotropins have been used to combat human infertility since the early 1930s.
After the discovery of the pituitary gonadotropins and their actions, researchers began
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harvesting animal pituitaries (mainly sheep and pigs) to administer the extracts
containing the gonadotropins to infertile women. Upon discovering disease transmission
that was linked to pituitary preparations, coupled with the production of antibodies as a
result of repeated injections of animal pituitary extract into women, urinary
gonadotropins began to be used instead (Lunenfeld 2004; Gibreel and Bhattacharya
2010). Gonadotropins are found in high quantities in the urine of post-menopausal
women due to the lack of estrogen production. A reduction in estrogen leads to an
increase in GnRH and subsequently more FSH and LH, which is eliminated through the
urine. Since the 1950s (when urine preparations were first used), many purification
techniques have been implemented and recently, only subjects from countries without
endemic prion disease in cows or humans are allowed to donate urine (Balen 2002).
Unfortunately, urinary-derived gonadotropins still harbor many impurities even after
multiple stages of purification (Bassett et al. 2009). A discovery of prion proteins in
urine samples from multiple animals, including humans, confirmed a need for safer
infertility treatments (Balen 2002; Lunenfeld 2004).
In the 1990s, recombinant preparations were implemented for human infertility
protocols, and researchers have since been attempting to make the safest, most efficient
recombinant gonadotropins possible. Many clinical trials have suggested that urinary
preparations are more reproductively efficient (Muasher et al. 2006; Gibreel and
Bhattacharya 2010) and more cost effective (Balasch and Barri 2001) than recombinant
preparations. There is opposing research suggesting that recombinant proteins are more
effective in terms of pregnancy rates (Balasch and Barri 2001) and the disease-harboring
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potential of the urinary preparations limits their use (Matorras and Rodriguez-Escudero
2002; Reichl et al. 2002). A ban on urinary gonadotropin preparations is in effect in
some European countries (similar to that placed on pituitary extracts), which validates the
cautionary use of urinary-derived gonadotropins. The difficulty in regulating and
monitoring the ~6000 donors that are necessary to fulfill the need for urinary-derived
gonadotropins each year (a level which will surely rise with increased demand), and the
fact that there are no minimum qualifications for donors, suggest and increased value for
recombinant proteins (Lunenfeld 2004).
The protocol for ovarian stimulation in humans begins with pharmacological
pituitary suppression using GnRH agonists or antagonists, allowing native production of
gonadotropins to increase. The endogenous production is supplemented by exogenous
hCG or recombinant FSH and/or LH allowing the ovary to be hyperstimulated, resulting
in a larger number of follicles to be collected. The oocytes are then surgically retrieved
and cultured until fertilization in vitro, resulting in embryo(s) that are placed into a
hospitable uterus for implantation and term pregnancy (Pauli et al. 2009).
Gonadotropin Background
FSH and LH are heterodimeric glycoprotein hormones consisting of an α- and βsubunit produced from the gonadotroph cells in the anterior pituitary gland. These
proteins, along with the other proteins within this family such as thyroid stimulating
hormone (TSH) and hCG (of placental origin), are the products of two separate genes.
The gene products are noncovalently associated after translation. The α-subunits within
this family are highly conserved amongst mammalian species, whereas the β-subunit
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confers specificity of receptor binding and are therefore distinct (Pierce and Parsons
1981).
Protein structure
The FSH and LH subunits contain disulfide bridges: 5 within the α-subunit and 6
within the β-subunit (Pierce and Parsons 1981; Furuhashi et al. 1994). Furuhashi et al.
(1994) demonstrated that when certain disulfide bonds were disrupted within the α
subunit, protein activity was lost by reducing secretion and/or increasing degradation,
while disrupting other disulfide bonds had no consequence on subunit interaction or
protein activity. It has also been suggested that despite disruption of one disulfide bond,
tertiary structure can be maintained; however, after two or more bonds are disrupted,
protein activity is lost, suggesting subunit and/or dimer structure had been compromised
(Giudice and Pierce 1979).
These glycoprotein hormones are stabilized by a cysteine knot formed by three
disulfide bridges in the center of the protein which creates large loops out of each subunit
(Xing et al. 2004a). Further stabilizing the FSH structure is a loop formed from the βsubunit around the α-subunit like a “seat-belt,” and a second smaller loop formed by the
β-subunit, both thought to be crucial for accurate receptor binding (Simoni et al. 1997;
Rose et al. 2000). The “seat-belt” region forms a hole within the β-subunit which houses
a glycosylated loop on the α-subunit, stabilizing the molecule even further (Xing et al.
2004a).
Post-translational modifications
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The primary reason recombinant gonadotropin production has been limited is a
result of the inability to effectively recreate post-translational modifications (namely
glycosylations) in certain heterologous systems. Both FSH and LH are posttranslationally glycosylated. There are two complex N-linked glycosylation sites on the
common α-subunit (N56 and N82) and two or one N-linked glycosylation sites on the
FSH (N13 and N30) and LH (N13) β-subunit, respectively (Pierce and Parsons 1981;
Wilson et al. 1990). As previously mentioned, in addition to the two N-linked
glycosylations, there is a unique ~25 amino acid domain on the placental-derived hCG βsubunit (Residues 122-146) called the CTP which is serine and proline rich, coding for
four O-linked glycosylation sites (Pierce and Parsons 1981).
As a consequence of different trimming and extension, the carbohydrates added to
FSH and LH are heterogeneous. These variations make up the ~20 FSH isoforms and
~39 LH isoforms that are produced in vivo depending on phase of estrous cycle as well as
age, sex, and parity of contributing animals (Stanton et al. 1993; D'Antonio et al. 1999;
Gibreel and Bhattacharya 2010). While FSH is more likely to include sialic acid
additions, LH is more likely to have sulfate groups incorporated into these glycosylations.
In fact, there are no known isoforms of LH that incorporate sialic acid residues (Green
and Baenziger 1988). Another carbohydrate frequently added to gonadotropins is
galactose. The carbohydrates are incorporated in varying configurations resulting in dior tri-branched structures providing a net negative charge to the protein (Green and
Baenziger 1988; Ulloa-Aguirre and Timossi 1998).
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Conventionally, glycosylations have been thought to increase biological activity
by protecting the core protein structure from proteases within the bloodstream of
mammals and reducing kidney and liver clearance (Morell et al. 1971; Sinclair and Elliott
2005). Fiete et al. (1991) discovered a receptor on liver endothelial cells that recognized
and bound the mannose residues found on the sulfonated side chains of human LH and
FSH (which are similar to those found on the bovine homolog), presumably allowing
isoforms with a higher degree of sulfonation to be cleared at a faster rate resulting in a
reduced biological activity (Wide et al. 2009). The specific amino acid residues
exhibiting the sulfonated glycosylation (Roseman and Baenziger 2000) and the sialylated
glycosylation (Bishop et al. 1994) may also be important in the recognition and disposal
of LH and FSH, respectively.
In addition, glycosylation increases solubility and stability of proteins, facilitates
proper protein folding, association with other subunits, appropriate charge, disulfide
bridge formation (Rose et al. 2000), and enzyme kinetics (Shental-Bechor and Levy
2009). The reason for these consequences is unclear, but the addition of sialic acid to the
nascent protein may be important as sialic acid is thought to increase half-life due to the
hydrophilic nature of the molecule, allowing it to maintain increased solubility in the
blood (Sinclair and Elliott 2005). FSH isoforms with higher sialic acid content have been
found to have an increased bioactivity, likely due to reduced clearance through the kidney
and liver (D'Antonio et al. 1999; Perlman et al. 2003). LH is not sialylated (Green and
Baenziger 1988), suggesting it’s half-life may not be as important for its function as a
result of the release patterns of LH versus FSH. FSH needs to be supplied continually to
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the cohort of follicles during the pre-deviation period for adequate maturation, suggesting
a longer bioactivity would be necessary (achieved by more glycosylations and the
addition of sialic acid), whereas LH only needs to function for a brief period based on the
length of the pre-ovulatory surge. Half-life may be inconsequential if the delivery
method can supply the gonadotropin to its target area before it can be broken down by
proteases, allowing for optimal bioactivity. Glycosylations may not be as important if a
steady supply of hormone initiates adequate receptor and intracellular response (BarriosDe-Tomasi et al. 2002).
Subunit assembly
It appears that as the individual subunits pass through the glycosylation apparati,
they become non-covalently associated within the endoplasmic reticulum, after the initial
glycosylations are added, and the disulfide bonds have been generated. A loop on the αsubunit which contains a glycosylation (residues 33-58) is “threaded” through a loop
within the β-subunit produced by the “seat-belt” region, and one of the disulfide bonds
(Xing et al. 2004a). As this “threading” is occurring, the latter disulfide bond is broken
and re-established after the α-subunit has positioned itself under the “seat-belt”,
subsequently allowing only harsh reducing agents to cause disassociation (Xing et al.
2004b). Along with the disulfide bonds, the aforementioned loop on the α-subunit
(termed the “long loop”) is also important in this association, based on mutagenesis
studies performed by Liu and Dias (1996) who demonstrated a loss of heterodimer when
a certain residue series was disrupted.
Gonadotropin function
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FSH is responsible for growth and maturation of multiple subordinate follicles
during a follicular wave within the ovary via granulosa cells in the female and facilitating
spermatogenesis by Sertoli cells in the male (Pierce and Parsons 1981; Wilson et al.
1990; Rose et al. 2000). LH is the trigger for ovulation of the dominant follicle(s) in
females and is responsible for release of testosterone from the Leydig cells of males
(Pierce and Parsons 1981; Simoni et al. 1999). FSH induces the aromatization of
androgens (supplied by the interstitial and theca cells) in the granulosa and Sertoli cells,
resulting in estrogen synthesis. LH triggers the synthesis of androgens such as
testosterone (Hillier et al. 1994).
Gonadotropin regulation at the neural level
FSH and LH respond to oscillations in expression of GnRH in the hypothalamus
through the action of the hypothalamic-pituitary axis. GnRH is released in a pulsatile
fashion from the hypothalamus which triggers an increase in expression and production
of LH and, to a smaller extent, FSH (Clarke and Pompolo 2005). The mechanism by
which GnRH stimulates transcription of the appropriate gonadotropin is not well
understood, but a number of possible intracellular signal pathways are activated by the
ligand-bound GnRH receptor (Thackray et al. 2010). The differential up-regulation of
specific gonadotropins could also be due to the frequency or amplitude of the pulses of
GnRH (Melamed 2010).
FSH and LH have been detected in fetal samples, suggesting the presence of
operational GnRH (Plant 2002; Delemarre et al. 2008); however, birth levels of FSH and
LH are undetectable and do not return until the onset of puberty. For this reason, puberty
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is defined as the “reactivation” of GnRH which first stimulates an increase of LH pulses
solely at night followed by the onset of a regular pulsatile pattern (Ebling 2005;
Delemarre et al. 2008). During the pre-pubertal period, levels of GnRH mRNA have
been measured at adult levels, but either an inhibitor prevents the protein from
functioning within the hypothalamus (gamma aminobutyric acid and neuropeptide Y are
potential candidates), or a stimulus has been taken away that was present during gestation
(kisspeptin receptor possibly; Plant 2002; Ojeda et al. 2006). Once puberty is
established, kisspeptin protein and receptor are detected within the hypothalamus which
is thought to stimulate GnRH release, subsequently resuming the episodic releases of
FSH and LH (Navarro et al. 2005; Roseweir and Millar 2009).
Inhibins, activins and follistatins are dimerized peptides produced primarily from
ovarian structures that have been shown to regulate the production of FSH and, to a lesser
extent, LH (Dupont et al. 2003; Thackray et al. 2010). Inhibin participates in a negative
feedback relationship with FSH. As more inhibin is produced, less FSH is produced from
the anterior pituitary because of antagonistic effects on the activin gonadotroph receptor,
rendering it useless (Rivier et al. 1986). Activin and follistatin work together in an
autocrine or paracrine fashion to regulate the expression of FSH β-subunit. Activin
directly up-regulates expression and follistatin binds activin to prevent FSHβ upregulation through activin receptor activation (Dupont et al. 2003; Bilezikjian et al. 2004;
Melamed et al. 2006).
Gonadotropin regulation at the ovarian level
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Cattle tend to have 2 or 3 follicular waves per estrous cycle (Adams et al. 1992;
Ginther et al. 1996), during which FSH is critical to the growth of the cohort of
subordinate follicles (Pierce and Parsons 1981). During the last follicular wave, one
follicle is set apart to become dominant (in a process termed divergence) and will
continue to ovulation while the remaining subordinate follicles become atretic and
regress (Ginther et al. 1996). Once the dominant follicle (DF) has been established and
as it advances towards ovulation, its dependence upon FSH is diminished due to the
increased expression of LH surface receptors on the granulosa cells and the decreased
expression of FSH receptors. At this time, FSH becomes unnecessary due to the newly
established reliance upon LH. Once the DF is established, it begins to produce inhibin
(Adams et al. 1992) and the subordinate follicles become less responsive to FSH as well
(Simoni et al. 1997). The subordinates also begin producing more estrogen, a negative
regulator of FSH (Thackray et al. 2010), due to the aromatization of androgens facilitated
by the newly established LH surface receptors (Richards and Hedin 1988; Ginther et al.
1996). Along with the up-regulation of LH receptors in the granulosa cells, estrogen
triggers the up-regulation of LH receptors on theca cells within the ovary (Richards and
Hedin 1988; Ginther et al. 1996). The increased expression of LH receptors prepares the
DF for an LH surge which culminates in ovulation (Dufau 1998).
Glycoprotein Hormone Receptor
The receptor for this class of peptide hormones is a G-protein coupled 7-pass
transmembrane receptor consisting of three domains: extracellular, transmembrane, and
C-terminal. There are marked differences between the FSH receptor (FSHR) and LH
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receptor (LHR), most being seen in the extracellular and C-terminal domains. The
extracellular domain is made of repeated motifs of about 24 residues called leucine-rich
repeats (LRR) that are important for protein-protein interactions, protein-receptor
binding, and cell-cell adhesion (Simoni et al. 1997). There are three and seven potential
glycosylation sites on the extracellular domain of the FSHR and LHR, respectively, with
only one being highly conserved. However, these sites do not appear to be necessary for
ligand binding (Davis et al. 1995; Simoni et al. 1997). The transmembrane domain
consists of seven hydrophobic motifs of 20-25 amino acids which become the α-helices,
three of the seven (motifs 2-4) being highly conserved between LHR and FSHR (~70%).
The C-terminal domain is thought to be involved in possible phosphorylation events and
membrane attachment (Simoni et al. 1997).
There is evidence for both FSHR and LHR transcripts that differ in size,
suggesting splice variations and/or different polyadenylation sites. Whatever the
mechanism, these variations can lead to alterations in ligand binding capacity and
receptor efficiency (Hillier et al. 1994; Simoni et al. 1997).
Gonadotropin receptor expression is cell-specific
The FSHR is limited in expression to Sertoli cells in the testes and granulosa cells
in the ovary. In the granulosa cells, there is an expression dichotomy depending upon the
level of expressed FSH; a low dose of FSH up-regulates FSHR gene expression whereas
a high dose of FSH down-regulates FSHR gene expression up to the time of luteinization
when FSHR protein becomes undetectable (Hillier et al. 1994; Simoni et al. 1997). The
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LHR is expressed in theca and granulosa cells of antral follicles in the ovary, as well as
Leydig cells of the testes (Hillier et al. 1994).
Receptor-protein interaction
Through mutagenesis studies, specific β-subunit regions of FSH and LH have
been identified as important for receptor binding. These include F33, R35, R42, S43, and
K44 for LH, and amino acids 93-99 of both LH and FSH (Rose et al. 2000). The amino
acids present in positions 93-99 are thought to wrap around the α-subunit like a “seatbelt” and allow for stabilization of receptor-protein binding (Simoni et al. 1997; Rose et
al. 2000). Some researchers also suggest an important role of the common α-subunit in
both receptor binding and in hormone action, as a result of glycosylation (Bishop et al.
1994; Valove et al. 1994; Zeng et al. 1995).
The current accepted model of receptor activation suggests hormone binding and
receptor activation are separate events involving separate receptor protein domains
(Simoni et al. 1997). Using chimeric receptors, the extracellular domain was determined
to be the sole contributor to ligand binding. Braun et al. (1991) suggested LRR 10 of the
extracellular domain was the region that conferred binding specificity. Receptor
activation and signal transduction have both been designated to the transmembrane
domain, but the importance of specific motiffs for each action has been disputed (Ji and Ji
1995; Rozzell et al. 1995). There are multiple theories proposed to the exact binding
mechanism, including a conformational change of the bound ligand eliciting signal
transduction (Braun et al. 1991; Cosowsky et al. 1995), and the LRR form into a shape
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complementary to the ligand allowing attachment based on complimentary charges (Jiang
et al. 1995).
There has been limited evidence of any cross reactivity between FSH and the
LHR and vice versa, suggesting tight regulatory control. Activating the LHR with FSH
or FSHR with LH has been limited to an excess of gonadotropin, specifically seen in
diseased states. Conversely, fish gonadotropin receptors exhibit adaptive mechanisms
where a gonadotropin can activate the opposite receptor (Bogerd et al. 2005).
Signal transduction includes production of cyclic adenosine monophosphate
(cAMP) as a secondary messenger, made evident by in vitro treatment of Sertoli and
granulosa cells with FSH (Means et al. 1980). The cAMP signal transduction pathway
(Figure 1.3, adapted from Simoni et al. 1997) results when cAMP is produced by
adenylyl cyclase that has been stimulated by the stimulatory subunit of the G-protein.
cAMP activates protein kinase A (PKA) in the female gonad and PKC in Sertoli cells,
which begins phosphorylation events leading to alteration in transcription patterns within
the genome. Some transcription factors that are activated from FSH and LH include
cAMP responsive elements binding proteins and modulators which assist in regulation of
hormone receptor expression, as well as aromatase synthesis (Simoni et al. 1997). Other
genes that may be induced as a result of FSH or LH stimulation are estrogen receptor 2,
inhibin α, PTGS2 (COX-2 associated), CYP19A1 (estrogen biosynthesis), HSD3B1
(progesterone synthesis), FSHR, and LHR (Mihm et al. 2006; Nimz et al. 2010).
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Figure 1.3 Cellular responses to FSH engaging G-protein coupled FSHR. Intracellular
response is mediated through AC which converts ATP to cAMP with the help of Gs. cAMP then
activates PK, which enters the nucleus to phosphorylate transcription factors. In the case of FSH,
the transcription factors trigger transcription of aromatase, which mediates the conversion of
androgen into estrogen, which affects the production of FSH in a negative feedback manner.
Abbreviations: FSHR: FSH receptor; AC: adenylyl cyclase; cAMP: cyclic AMP; Gs: stimulatory
subunit of G protein.
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CHAPTER TWO
PRODUCTION AND ANALYSIS OF RECOMBINANT BOVINE FOLLICLE
STIMULATING HORMONE FROM TWO HETEROLOGOUS HOSTS

Abstract
Follicle stimulating hormone (FSH) is a heterodimeric pituitary-derived
glycoprotein hormone that is responsible for growth and maturation of follicles in
females and steroidogenesis in males. FSH is harvested from pituitary glands of
slaughtered animals and used in superovulatory protocols. This method of collection has
many drawbacks, including contamination with other pituitary proteins, inconsistencies
between batches, and the possibility for disease transmission. Recombinant bovine FSH
(bFSHβα) was produced from bacteria and yeast heterologous expression systems, and
the ovarian weight gain biological activity assay was performed. Bacterial-derived
rbFSHβα was found to increase rat ovarian weight when compared to vehicle-only
control rats, as well as pituitary-derived FSH treated rats, suggesting the recombinant
protein retains biological activity. Yeast-derived rbFSHβα did not increase rat ovarian
weights when compared to vehicle-only control rats, however, lack of biological activity
cannot be concluded because the pituitary-derived FSH treated rats (positive control) did
not demonstrate an increase in ovarian weight either.
Introduction
FSH is a heterodimeric pituitary-derived glycoprotein hormone that is responsible
for growth and maturation of follicles in females and steroidogenesis in males. FSH is
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the product of two genes which encode distinct subunits (α and β) that are non-covalently
associated post-protein synthesis. The α-subunit is conserved within this family of
glycoprotein hormones [luteinizing hormone, human chorionic gonadotropin (hCG), and
thyroid stimulating hormone] whereas the β-subunit is different and confers receptor
specificity (Pierce and Parsons 1981; Rose et al. 2000).
FSH is used in the cattle industry as an integral part of the superovulation
protocol. At the beginning of a follicular wave, pituitary-derived porcine FSH (adequate
species cross-reactivity has been demonstrated) is administered to trigger the
development of more than one dominant follicle (typical estrous cycle results in a single
dominant follicle and ovulation). FSH has conventionally been derived from pituitary
tissue, despite concerns that include contamination with other pituitary hormones such as
LH (Kafi and McGowan 1997; Galli et al. 2003; Adams and Boime 2008), batch-to-batch
variation (Murphy et al. 1984; Kanitz et al. 2002; Galli et al. 2003), and potential for
prion transmission (the causative agent of bovine spongiform encephalopathy; Galli et al.
2003; Adams and Boime 2008). Here, we provide evidence that a recombinant FSH
could provide a safe alternative that is devoid of contaminating pituitary hormones for
superovulation protocols.
Materials and Methods
Bacterial 6-his tagged protein production
A fusion construct of bovine FSH with the β subunit directly upstream of the αsubunit (to yield bFSHβα) was generated by PCR using cDNA from bovine anterior
pituitary tissue (see Table D.2 for primer sequences). This gene product was ligated into
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pQE30 for expression of an N-terminal six-histidine (6his) tagged fusion protein.
Following transformation of the construct into M15 bacterial cells, cultures were grown
to OD600 of 0.6 in ECPM1 media (Barnard and Payton 1995) at 37oC, induced with
isopropylthio-β-D-galactoside (IPTG; 250 µM), and protein expressed overnight at room
temperature. After expression, cells were collected by centrifugation (2000 x g; 30 min;
4oC), lysed by cell disruption in a French press (28,000 psi), and insoluble material was
separated by centrifugation (10,000 x g, 30 min, 4oC). bFSHβα in the soluble fraction
was purified by nickel affinity chromatography (Ni-NTA Agarose, Qiagen, Valencia,
CA) yielding a partially pure protein. Purification fractions and induced cell pellets were
analyzed using 12% SDS-PAGE stained with Coomassie Brilliant Blue. Protein was
transferred from acrylamide gels to nitrocellulose at 16 V for 40 min (TransBlot SD Semi
Dry Transfer Cell, BioRad, Hercules, CA). Western blotting was performed with
blocking (1% non-fat milk) for 1 hr, and the following antibodies: 1o mouse α-6his
(1:2000) or 1o α-ovine FSH (1:250) incubation for 1 hr, and 2o goat-α-mouse (GαM)
horseradish peroxidase (HRP; 1:5000) incubation for 1 hr. HRP was visualized using
SuperSignal® West Pico Chemiluminescent Substrate Kit (Pierce®, Rockford, IL).
Protein concentration was determined using BCA Assay kit (Pierce®, Rockford, IL) with
bovine serum albumin as a standard, and lyophilized in 50 µg aliquots for storage.
Bacterial GST-tagged protein production
A fusion construct of bovine FSH with the β subunit directly upstream of the αsubunit (to yield bFSHβα) was generated by PCR using cDNA from bovine anterior
pituitary tissue (see Table D.2 for primer sequences). This gene product was ligated into
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pGEX4T-1 for expression of a glutathione-S-transferase (GST) tagged fusion protein
(GST is a 27 kDa protein). Supercoiled plasmid was transformed into BL21(DE3)
competent cells via electroporation and positive transformants containing bFSHβα were
confirmed initially by PCR on whole cells and then by DNA sequencing (Clemson
University Genomics Institute-CUGI). Following transformation of the construct,
cultures were grown to OD600 of 0.6 in terrific broth media (1% tryptone, 2.5% yeast
extract, 0.4% glycerol, 17 µM KH2PO4, 72 µM K2HPO4) at 37oC, induced with IPTG
(250 µM), and protein expressed overnight at room temperature. After expression, cells
were collected by centrifugation (2000 x g; 30 min; 4oC), lysed by sonication, and
insoluble material was separated by centrifugation (10,000 x g, 30 min, 4oC). bFSHβα in
the soluble fraction was purified by affinity chromatography utilizing the GST tag
incorporated by the expression vector. Purification fractions and induced cell pellets
were analyzed using 12% SDS-PAGE stained with Coomassie Brilliant Blue. Protein
was transferred from acrylamide gels to nitrocellulose at 16 V for 40 min (TransBlot SD
Semi Dry Transfer Cell, BioRad, Hercules, CA). Western blotting was performed with
blocking (1% non-fat milk) for 1 hr, and the following antibodies: 1o α-GST-biotin
(1:2000) or 1o α-ovine FSH (1:250) incubation for 1 hr, and 2o α-biotin HRP (1:5000)
incubation for 1 hr. HRP was visualized using SuperSignal® West Pico
Chemiluminescent Substrate Kit (Pierce®, Rockford, IL). Protein concentration was
determined using BCA Assay kit (Pierce®, Rockford, IL). Protein was quantified using
BCA assay (Pierce®, Rockford, IL).
Yeast protein production
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A fusion construct of bovine FSH with the β subunit directly upstream of the αsubunit (to yield bFSHβα) was generated by PCR using cDNA from bovine anterior
pituitary tissue (see Table D.5 for primer sequences). This gene product was ligated into
pPICZαA for expression of a C-terminal 6his tagged fusion protein. Plasmid (5 µg) was
linearized using BstX1 to prepare for transformation and subsequent integration into the
Pichia pastoris genome. GS115 P. pastoris competent cells were transformed by
electroporation (1500 V; ECM830, BTX, Holliston, MA). Transformants were then
plated on yeast extract peptone dextrose media containing 100 µg/ml Zeocin and
incubated at 30oC for 3-10 days. Positive transformants containing bFSHβα were
determined using PCR on whole cells and confirmed by DNA sequencing (CUGI). The
methanol utilization phenotype was determined by growth on media containing histidine
and either dextrose or methanol; bFSHβα was found to exhibit the MutS phenotype,
meaning it utilizes methanol for protein expression at a relatively slow rate when
compared to wild-type. A culture of buffered minimal glycerol was seeded with a single
positive colony and grown to OD600 of 2-6 (30oC, 20 h). The cells were harvested by
centrifugation (1500 x g, 10 min, 27oC) and resuspended to an OD600 of 1 in buffered
minimal methanol media. Cells were induced with 0.5% methanol and incubated at 30oC
(1-4 days). Cultures were then harvested by centrifugation (1500 x g, 10 min),
resuspended in 20 mM Tris (pH 7.4), and cells loaded into a bead beating chamber and
lysed with 0.5 mm glass beads for 3 min (Model 1107900, BioSpec Products Inc,
Bartlesville, OK). The resulting slurry was centrifuged (200 x g, 10 min), and soluble
material was separated from the glass beads and insoluble material by centrifugation
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(10,000 x g, 30 min, 4oC). Protein was purified beginning with ion exchange HPLC
(QHP 5 ml column; GE Healthcare, Piscataway, NJ) using a 10-40% gradient of 1 M
NaCl with protein eluted in 20 mM Tris, pH 7.4. Size exclusion HPLC followed using
G50 resin (GE Healthcare, Piscataway, NJ) with protein eluted in PBS (pH 7.4). Protein
was analyzed from spent culture media, induced cell pellet, and all purification fractions
using 12% SDS-PAGE stained with Coomassie Brilliant Blue. Protein was transferred
from acrylamide gels to nitrocellulose at 16 V for 40 min (TransBlot SD Semi Dry
Transfer Cell, BioRad, Hercules, CA). Western blotting was performed as follows: 1%
non-fat milk block for 1 hr, 1o mouse α-6his antibody (1:2000) or 1o α-ovine FSH (1:250)
incubation for 1 hr, and 2o GαM HRP incubation for 1 hr. HRP was visualized using
SuperSignal® West Pico Chemiluminescent Substrate Kit (Pierce®, Rockford, IL).
Protein was quantified using BCA assay (Pierce®, Rockford, IL) and stored in PBS at 20oC until further use.
In vivo biological assay
To assess biological activity, the rat ovarian weight gain assay was utilized
(Steelman and Pohley 1953). Briefly, 3 µg recombinant bFSHβα or commerciallyavailable native pituitary-derived porcine FSH (Bioniche Animal Health, Belleville,
Ontario, Canada) was administered to peri-mature (Day 20-22) Sprague-Dawley female
rats in three 0.5 ml IP injections in saline plus hCG (100 IU/ml) 24 hours apart. Inclusion
of hCG serves to increase sensitivity of the rat to the exogenous FSH and was provided to
all subjects prior to FSH treatment. All animals were kept 5 to a cage with ad libitum
food and water, at a constant temperature (22oC) and light cycle (12 h light). All animal
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protocols were conducted in accordance to IACUC regulations. Rats were euthanized 24
hours after the third injection (72 hours from initiation of treatment) and ovaries excised
and weighed. Ovarian weights were analyzed using Student’s t-test to identify
differences among groups (α = 0.05).
Results
Protein production
Recombinant bacterial bFSHβα (rbbFSHβα)-6his protein was estimated to be
~10% pure, as judged by Coomassie staining (Figure 2.1) though this estimation is likely
inaccurate due to poor stain binding by bFSHβα. Purification of rbbFSHβα-GST protein
was complicated by two issues. First, protein did not bind efficiently to the GST-affinity
column during protein purification. Second, an excess of free GST was produced from
the bacteria during induction (Figure 2.2). Re-sequencing revealed a frame-shift in the
GST gene, resulting in the loss of a functional protein, explaining loss of binding. Recloning attempts of the expression cassette were unsuccessful.
Small-scale expression cultures revealed that adequate amounts of recombinant
yeast bFSHβα (rybFSHβα) protein were produced after 1 day of induction (Figure 2.3).
Purified protein from a large-scale expression was concentrated at ~73 µg/ml and purity
was ~ 90% (Figure 2.4).
In vivo biological assay-Trial 1
Bacterial-derived bFSHβα-6his protein (3 µg) was delivered over three doses
(each 24 h apart) to Sprague-Dawley female rats (n = 10). rbbFSHβα-6his treatment
triggered an increase in rat ovarian weights when compared to control rats (22.0 ± 1.2 mg
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Figure 2.1 Purification fraction of rbbFSHβα-6his from M15 bacterial cells.
A: 15% SDS-PAGE stained with CBB, B: Pituitary porcine FSH (pFSH) preparation western blot
probed with α-ovine-FSH 1o (1:250), rbbFSHβα-6his preparation western blot probed with αovine FSH 1o (1:250), rbbFSHβα-6his preparation western blot probed with α-6his tag 1o
(1:2000).

Figure 2.2 rbbFSHβα-GST protein produced from BL21(DE3) bacterial cells. A: Western
blot of GST purification fractions probed with 1o α-GST Biotin antibody (1:2000) and 2o HRPBiotin (1:5000). B: Coomassie stain of 12% SDS-PAGE.
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Figure 2.4 rybFSHβα-6his protein induced from P.
pastoris. Yeast cells were induced for 1 day at 28oC. Cell pellet
Figure 2.3 Small-scale expression study of rybFSHβα-6his.

was lysed using bead beater and protein was purified from

Protein was induced at 30oC from P. pastoris yeast cells for 1-6

soluble fraction using ion exchange and size exclusion HPLC. A:

days. Analysis was performed on samples of pelleted cells (CP)

CBB stain of purification fractions, B: Western blot of

or spent culture supernatant (CS) by western blot using 1o mouse

purification fractions using 1o mouse α-6his (1:2000), 2o GαM

α-6his (1:2000), 2o GαM HRP (1:5000).

HRP (1:5000).
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vs. 15.5 ± 0.8 mg, respectively; p < 0.05), and a ~15% increase over native pituitaryderived FSH (18.7 ± 1.3 mg; p < 0.05; Figure 2.5). There were no overall differences in
whole rat weights for recombinant protein treatment (48.1 ± 1.0 g) or native protein
treatment (46.2 ± 1.1 g) when compared to control rats (47.8 ± 0.6 g; p > 0.05).
In vivo biological assay-Trial 2
Yeast-derived bFSHβα-6his protein (10 µg) was delivered over three doses (each
24 h apart) to Sprague-Dawley female rats (n = 10). Analysis suggested whole rat
weights decreased with both pituitary-derived and recombinant FSH treatments (44.8 ±
2.4 g and 47.2 ± 3.6 g, respectively) when compared to the vehicle-only rats (53.0 ± 3.6
g; p < 0.1; Figure 2.6). Pituitary-derived FSH (0.76 ± 0.09 mg/g) and rybFSHβα-6his
(0.79 ± 0.16 mg/g) treatments triggered an overall decrease in rat ovarian weights (mg) as
a portion of the rat’s body weight (g) when compared to control rats (0.84 ± 0.13 mg/g; p
> 0.05; Figure 2.7).
Discussion
The data from Trial 1 suggest that in the rodent model, the lack of glycosylation
of the recombinant protein did not eliminate biological activity, as the ovarian weights in
treated rats increased after delivery of bacterial-derived recombinant bFSHβα (Figure
2.5). It is possible that the contaminating proteins in the sample had some consequences
on ovarian weight. The yeast-derived protein used in Trial 2 cannot be assumed to be
inactive based on the data because the native, pituitary FSH (positive control) group did
not trigger an increase in ovarian weight, as expected (Figure 2.7). In addition, rat body
weights were increased in the vehicle-only controls when compared to both treatments,
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Figure 2.5 Ovarian weights from rats injected with rbbFSHβα-6his in Trial 1. Ovarian weights of peri-mature female rats injected
with bacterial-derived recombinant bFSHβα-6his, native pituitary-derived commercially-available pFSH, or hCG (100 IU/ml). Dosage of
FSH (3 µg/animal for both recombinant and native) was based on adjustment of dose commonly given to dairy cattle. **Significant
difference for treatment vs. control (p < 0.05); n = 20 for each group.
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Figure 2.6 Rat body weights after injection with rybFSHβα-

Figure 2.7 Ovarian weights of rats injected with

6his in Trial 2. Whole rat body weights post-mortem after

rybFSHβα-6his in Trial 2. Rat ovarian weights (mg)/body

treatment with either vehicle only (hCG), 10 µg pituitary-derived

weight (g) post-mortem after treatment with either vehicle only

pFSH, or 10 µg rybFSHβα-6his. **Significant difference for

(hCG), 10 µg pituitary-derived pFSH, or 10 µg rybFSHβα-6his.

treatment vs. control (p < 0.05); n = 10 for each group.

*Significant difference for treatment vs. controls (p < 0.1); n =
10 for each group.
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which may explain the increase in ovarian weights (Figure 2.6). Conversely, the yeast
cells did not secrete this protein as expected, suggesting the rybFSHβα may have been
improperly glycosylated (hyper- or hypo-). The improper glycosylations could account
for the lack of bioactivity of the recombinant protein.
The biological half-life of FSH has conventionally been attributed to the
incorporation of sialic acid into the N-linked post-translational glycosylations of the
mammalian protein (Green and Baenziger 1988; Morell et al. 1971; Sinclair and Elliot
2005). Bacteria do not glycosylate their proteins and yeast tend to hyperglycosylate their
proteins, with neither variety exactly mimicking a mammalian protein (Porro 2005). The
lack of proper glycosylations is what has limited use of non-eukaryotic heterologous
protein expression systems, as there are concerns that the protein will not be active long
enough in vivo to cause desired effects.
In vivo activity of recombinant bFSH has been reported, and a few production
systems have been utilized to produce a biologically active protein, including Chinese
Hamster Ovary (CHO) cells and plant systems. Both Looney et al. (1988) and Wilson et
al. (1993) superovulated cattle with a recombinant bFSH prepared from CHO cells, and
found it to increase the number of recovered embryos. Even though CHO cells are a
mammalian system, they are not the ideal protein production system for use in
mammalian industries because of their need for fetal bovine serum (FBS) in culture
media and the potential of that to transmit disease-causing organisms (Balen 2002).
Recently, active human FSH (hFSH) was produced from modified CHO cells that can
grow in the absence of FBS (Kim et al. 2010). Dirnberger et al. (2001) produced
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recombinant bFSH from transgenic tobacco plants and found the recombinant protein
increased the number of recovered oocytes, but not as efficiently as a traditional hyperstimulatory drug, pregnant mare serum gonadotropin.
Production of hFSH typically involves CHO heterologous system, and has
recently focused on the addition of extra glycosylations to enhance the protein’s
biological activity, thereby reducing the amount or frequency of FSH injections for
superovulation (Fares et al. 1992; Devroey et al. 2004; Lemke et al. 2008). Other reports
have produced recombinant ovine and porcine FSH, but only in vitro data was reported,
lending limited insight to glycosylations and their link to biological half life (Fidler et al.
1998; Richard et al. 1998; Fidler et al. 2003).
Conclusions
Having shown targeted effects in a rodent model, further research with bacterialderived recombinant bFSHβα would be warranted using a bovine model, the final
destination for the exogenous FSH produced here. This bioactive heterologous protein
may, in the future, serve as a safer, more pure alternative to pituitary-derived FSH.
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CHAPTER THREE
PRODUCTION AND ANALYSIS OF RECOMBINANT BOVINE LUTEINIZING
HORMONE FROM TWO HETEROLOGOUS HOSTS

Abstract
Luteinizing hormone (LH) is a glycoprotein produced in the anterior pituitary that
is responsible for ovulation of the dominant follicle in the ovary, and the release of
testosterone from Leydig cells within the testes. LH is composed of 2 subunits (α and β)
that are noncovalently associated post-translation. The stimulatory agent of LH,
gonadotropin releasing hormone (GnRH), is used in the cattle industry to synchronize
ovulation within cattle populations, however, studies have shown that GnRH is not as
consistent as LH in this task. Here, we describe successful efforts to produce highly pure
recombinant bovine LH (bLH) from two heterologous hosts, bacteria and yeast. Each of
these bLH preparations was used to determine in vitro (receptor binding and activation
capacity) and in vivo (biological) activity when compared to a commercially available LH
pituitary preparation.
Introduction
LH is a heterodimeric glycoprotein hormone produced within the anterior
pituitary. LH, along with follicle stimulating hormone (FSH), thyroid stimulating
hormone, and chorionic gonadotropin, is composed of two subunits produced from
different genes that are non-covalently associated post-translation. The α-subunit within
this family of hormones is conserved, whereas the β-subunit is specific for each protein,
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conferring receptor specificity (Pierce and Parsons 1981). LH is responsible for
ovulation of the dominant follicle within the ovary, and the release of testosterone from
Leydig cells within the testes. LH is strictly regulated by GnRH which is released from
the hypothalamus and travels the hypothalamic-hypophyseal axis (Pierce and Parsons
1981; Simoni et al. 1999).
GnRH, rather than LH, is used in bovine superovulatory protocols to trigger
ovulation because of the tight consequential regulation between the two hormones;
however, it also has been linked to the regulation of FSH, albeit a looser correlation
(Clarke and Pompolo 2005). Despite being the conventional ovulatory stimulator in
synchronization protocols (Pursley et al. 1995), GnRH has been shown to be less
effective than pituitary LH at stimulating ovulation (56% and 78%, respectively) in dairy
heifers, however both products induced a new follicular wave within 2 days posttreatment if that treatment resulted in ovulation (Martinez et al. 1999). GnRH is used in
bovine superovulation because of problems documented of pituitary-derived hormones,
including contamination of other pituitary hormones (Kafi and McGowan 1997; Galli et
al. 2003; Adams and Boime 2008), batch inconsistencies (Murphy et al. 1984; Kanitz et
al. 2002; Galli et al. 2003), and the potential to spread disease causing agents, such as
prions (Galli et al. 2003; Adams and Boime 2008). These issues are of enough concern
to warrant the ban of such products in some European countries (Galli et al. 2003). To
combat these issues, recombinant proteins have been manufactured for superovulatory
use (main focus to date has been FSH), but have not become widespread yet. A
recombinant preparation would need to be produced from a mammalian vector (namely
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Chinese hamster ovary cells) to look most identical to the native protein, but the potential
for spreading disease via prions may still be present from the inclusion of fetal bovine
serum in the culture media (Balen 2002). Instead, it may be possible to produce a
recombinant protein from a non-mammalian host (such as bacteria or yeast) that acts
identical, if not better, than a protein produced from a mammalian vector, eliminating the
possibilities of disease transmission. Recombinant proteins also eliminate another
notable problem of pituitary-derived hormones, that of contamination of other pituitary
hormones. The issue of hormone contamination and whether a superovulatory
preparation needs both FSH and LH to be most effective has been debated (Ward 1986;
Takagi et al. 2001; Kanitz et al. 2002). A recombinant preparation of bLH would be
useful to the bovine superovulation industry.
In this study, bacterial- (rbbLHβα) and yeast-derived (rybLHβα) recombinant
versions of LH were produced and their activity compared using an in vitro bovine
granulosa cell assay to measure gene expression profiles. The genes considered included
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, which served as the reference
gene), CYP19A1, a marker for estrogen biosynthesis, and FSH and LH receptor (FSHR
and LHR, respectively). Additionally, an in vivo biological activity assay was performed
to measure ascorbic acid oxidation in the rodent ovary.
Materials and Methods
Vector construction
The bLHβ, and the common α subunit were amplified via PCR using bovine
anterior pituitary cDNA (primer sequences can be found in Table D.2 and D.5). Using
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novel restriction enzyme sites, bLHβ was cloned directly upstream of α in a bacterial
expression vector (pGEX4T-1) and a yeast expression vector (pPICZαA).
E. coli expression
Supercoiled plasmid was transformed into BL21(DE3) competent cells via
electroporation and positive transformants containing bLHβα were confirmed initially by
PCR on whole cells and then by DNA sequencing (Clemson University Genomics
Institute—CUGI). Following transformation of the construct, cultures were grown to
OD600 of 0.6 in ECPM1 media (Barnard and Payton 1995) at 37oC, induced with IPTG
(250 µM), and protein expressed overnight at room temperature. After expression, cells
were collected by centrifugation and lysed by cell disruption and insoluble material was
separated by centrifugation (10,000 x g, 30 min, 4oC). bLHβα in the soluble fraction was
purified by affinity chromatography utilizing the N-terminal glutathione s-transferase
(GST) tag incorporated by the expression vector. Protein was then purified using ion
exchange HPLC (QHP 5 ml column; GE Healthcare, Piscataway, NJ) using a 10-40%
gradient of 1 M NaCl with protein eluted in 20 mM Tris, pH 7.4. Size exclusion HPLC
followed using G50 resin (GE Healthcare, Piscataway, NJ) with protein eluted in PBS
(pH 7.4). Purification fractions and induced cell pellets were analyzed using 12% SDSPAGE stained with Coomassie Brilliant Blue. Protein was transferred from acrylamide
gels to nitrocellulose at 16 V for 40 min (TransBlot SD Semi Dry Transfer Cell, BioRad,
Hercules, CA). Western blotting was performed with blocking (1% non-fat milk) for 1
hr, and the following antibodies: 1o α-GST-biotin (1:2000) or 1o α-ovine FSH (1:250)
incubation for 1 hr, and 2o α-biotin horseradish peroxidase (HRP; 1:5000) incubation for
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1 hr. HRP was visualized using SuperSignal® West Pico Chemiluminescent Substrate
Kit (Pierce®, Rockford, IL). Protein was quantified using BCA assay (Pierce®,
Rockford, IL).
P. pastoris expression
pPICZαAbLHβα plasmid (5 µg) was linearized using BstX1 to prepare for
transformation and subsequent integration into the Pichia pastoris genome. GS115 P.
pastoris competent cells were prepared and transformed by electroporation (ECM830,
BTX, Holliston, MA, 1500 V). Transformants were then plated on yeast extract peptone
dextrose media containing 100 µg/ml Zeocin and incubated at 30oC for 3-10 days.
Positive transformants containing bLHβα were determined using PCR on whole cells and
confirmed by DNA sequencing (CUGI). The methanol utilization phenotype was
determined by growth on media containing histidine and either dextrose or methanol;
bLHβα was found to exhibit the Mut+ phenotype, meaning it utilizes methanol to express
heterologous proteins at a normal rate when compared to wild-type. A culture of
buffered minimal glycerol was seeded with a single positive colony and grown until
OD600 of 2-6 (30oC, 20 h). The cells were harvested by centrifugation (1500 x g, 10 min,
27oC) and resuspended to an OD600 of 1 in buffered minimal methanol media. Cells were
induced with 0.5% methanol and incubated at 30oC (1-6 days). Cultures were then
harvested by centrifugation (1500 x g, 10 min), resuspended in 20 mM Tris (pH 7.4), and
cells loaded into a bead beating chamber and lysed with 0.5 mm glass beads for 3 min
(Model 1107900, BioSpec Products Inc, Bartlesville, OK). The resulting slurry was
centrifuged (200 x g, 10 min), and soluble material was separated from the glass beads
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and insoluble material (10,000 x g, 30 min, 4oC). Protein was purified beginning with
ion exchange HPLC (QHP 5 ml column; GE Healthcare, Piscataway, NJ) using a 10-40%
gradient of 1 M NaCl with protein eluted in 20 mM Tris, pH 7.4. Size exclusion HPLC
followed using G50 resin (GE Healthcare, Piscataway, NJ) with protein eluted in PBS
(pH 7.4). Purification fractions and induced cell pellets were analyzed using 12% SDSPAGE stained with Coomassie Brilliant Blue. Protein was transferred from acrylamide
gels to nitrocellulose at 16 V for 40 min (TransBlot SD Semi Dry Transfer Cell, BioRad,
Hercules, CA). Western blotting was performed with blocking (1% non-fat milk) for 1
hr, and the following antibodies: 1o mouse α-6his (1:2000) or 1o α-ovine FSH (1:250)
incubation for 1 hr, and 2o goat-α-mouse (GαM) HRP (1:5000) incubation for 1 hr. HRP
was visualized using SuperSignal® West Pico Chemiluminescent Substrate Kit (Pierce®,
Rockford, IL). Protein was quantified using BCA assay (Pierce®, Rockford, IL).
In vitro assay
Bovine ovaries (~1 kg) were obtained from a local abattoir (Brown Packing Co.,
Gaffney, SC) and rinsed in PBS, 70% ethanol, and M199 with 0.1% BSA. Follicles >10
mm were removed and granulosa cells isolated and collected in M199 (0.1% BSA, 10
µg/ml DNase, 50 U/ml Heparin), followed by filtration (100 µm cell strainer, BD
Biosciences, Billerica, MA). Granulosa cells were then washed four times in M199
(0.1% BSA) and resuspended in M199 (0.1% BSA, 1 µg/ml insulin, 10% FBS). Cells
were counted using a hemocytometer and 3 x 105 cells were plated in 24 well culture
plates (amine coating; BD Biosciences, Billerica, MA). Treatments (in 100 µl vehicle)
were as follows: PBS (vehicle), 50 µunits pituitary ovine LH (Sigma, St. Louis, MO),
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rbbLHβα (20 µg), and rybLHβα (20 µg). Treatments were added and cells were plated
overnight at 37oC. After four days, cells were trypsinized, counted, and stored at -20oC
until analysis. All reagents were purchased from Sigma (St. Louis, MO) unless otherwise
noted. Culture supernatant was assayed for progesterone content using a Coat-A-Count®
progesterone RIA (Siemens Healthcare Diagnostics, Deerfield, IL) that measures binding
competition of radiolabeled progesterone to antibody.
qReal Time PCR
Total RNA was isolated from granulosa cell pellets using AurumTM Total MRNA
Mini Kit (BioRad, Hercules, CA), followed by RQ1 RNase-free DNase treatment for 30
min at 37oC (10 units; Promega, Madison, WI). DNA degradation was confirmed using
conventional PCR and primers specific to the reference gene. RNA was quantified using
a NanoDrop 8000 Spectrophotometer (ThermoScientific, Wilmington, DE). First strand
cDNA was synthesized from 30 ng total RNA in 20 µl reaction using ProtoScript® MuLV
First Strand cDNA Synthesis kit (New England Biolabs, Ipswich, MA) using a random
hexamer primer (50 µM), 1 unit reverse transcriptase, and the following conditions:
denaturation at 70oC for 5 min, annealing at 25oC for 5 min, extension at 42oC for 1 hr,
inactivation of reverse transcriptase at 80oC for 10 min. cDNA was then treated with
RNaseH for 20 min at 37oC (New England Biolabs, Ipswich, MA).
Gene specific primers were used for the following genes: GAPDH, CYP19A1,
FSHR, and LHR (Nimz et al. 2010; Table D.6). Quantitative real time PCR (qPCR) was
conducted using iScriptTM RT-PCR Kit with SYBR® Green (BioRad, Hercules, CA) in an
iQ5 iCycler Multicolor Real-Time PCR Detection System (BioRad, Hercules, CA) under
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the following cycling conditions: pre-incubation at 95oC for 5 min, 40 cycles of
denaturation at 95oC for 10 s, fluorescence collection at 60oC for 30 s. The reaction used
6 µl cDNA and 5 µM each forward and reverse primers in a 26 µl reaction. The melt
curve analysis was obtained to ensure appropriate products were made with no primer
dimerization. Primer efficiencies were determined to be >95% for each primer set.
qPCR products were visualized by agarose gel electrophoresis (1%) and stained with 1 µg
ethidium bromide.
In vivo assay
To assess biological activity, the LH ovarian ascorbic acid depletion assay was
utilized (Goldstein and Sturgis 1961). All animals were kept three to a cage with ad
libitum food and water, at a constant temperature (22oC) and light cycle (12 h light). All
animal protocols were conducted in accordance to IACUC regulations. Briefly, 26 dayold Holtzman rats were made to be pseudopregnant by administration of PMSG (50 IU)
followed by hCG (25 IU) 48 h later (either 0.5 cc or 0.25 cc IP injections in 0.9% saline,
respectively). Four days after the last injection, each rat’s right ovary was surgically
removed, immediately placed on ice, and stored at -20oC until further analysis. Directly
following unilateral ovariectomy, each rat randomly received an LH treatment (0.25 cc
IV injection in 0.9% saline). The treatments were as follows: PBS (vehicle), pituitary
ovine LH (50 µunits), rbbLHβα (20 µg), or rybLHβα (20 µg). Three hours later, each
rat’s left ovary was surgically removed and prepared as previously described for storage.
Following the second ovariectomy, rats were euthanized following appropriate animal
guidelines. Each ovary was homogenized using a Dounce homogenizer (50 passes) and
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cell lysis was confirmed by visualization by microscopy (10X). Cellular debris was
removed by centrifugation (10,000 x g, 10 min, 4oC) and soluble contents were
deproteinated using 10 kDa NMWL centrifugal unit (Millipore, Jaffrey, NH). Ascorbic
acid was measured spectrophotometrically (560nm) from the eluate using an ascorbic
acid assay kit (MBLI, Woburn, MA). Briefly, a catalyst oxidizes ascorbic acid in the
sample into a product that interacts with a probe, causing a colorimetric change.
Results
Protein production
After optimal expression and purification conditions were determined, highly pure
bacterial- and yeast-derived LH preparations were obtained. rbbLHβα was estimated to
be >90% pure and quantified at 205 µg/ml (Figure 3.1). An expression time course
suggested the optimal induction time for rybLHβα was 5-6 days at 28oC (Figure 3.2), and
purified protein was estimated to be >95% pure and quantified at 207 µg/ml (Figure 3.3).
In vitro assay
After one day of LH treatment, there was a slight increase in transcript level of
CYP19A1 estrogen biosynthesis gene for all LH treatments (pituitary LH: 0.44-fold
increase, rbbLHβα: 0.12-fold increase, rybLHβα: 0.40-fold increase). Transcript level of
FSHR gene decreased similarly throughout each LH treatment (pituitary LH: 2.5-fold
decrease, rbbLHβα: 1.2-fold decrease, rybLHβα: 1.3-fold decrease). Transcript level of
LHR gene also decreased, but a larger decrease was seen in the pituitary LH and the
rybLHβα treatments (7.4-fold decrease and 2.9-fold decrease, respectively), as compared
to the rbbLHβα treatment (1.2-fold decrease; Figure 3.4A).
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Figure 3.1 rbbLHβα protein induced from E. coli bacterial

Figure 3.2 Small-scale expression study of rybLHβα in P.

cells overnight at RT. Cell pellet was lysed using cell

pastoris yeast. Protein was induced with the addition of 2%

disruption and protein was purified from soluble fraction using

galactose at 28oC for 1-6 days. Analysis was performed on small

ion exchange and size exclusion chromatography. A: CBB stain

samples of pelleted cells (CP) or spent culture supernatant (CS)

of final purified fraction. B: Western blot of final purified

using 1o mouse α-6his (1:2000), 2o GαM HRP (1:5000).

purification fraction using 1o α-GST-Biotin (1:2000), 2o GαM
HRP (1:5000).
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Figure 3.3 rybLHβα protein induced from P. pastoris yeast cells. Protein expression was induced for 5 days at 28oC. Cell pellet was
lysed using bead beater and protein was purified from soluble fraction using ion exchange and size exclusion chromatography. A: Silver
stain of purification fractions. B: Western blot of purification fractions using 1o mouse α-6his (1:2000), 2o GαM HRP (1:5000).
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Progesterone concentrations were determined by a progesterone RIA of the
culture supernatant after one day of incubation with the LH treatments. Cells treated with
vehicle expressed 21.7 ± 6.4 ng/ml progesterone, compared to 27.1 ± 1.9 ng/ml seen in
the cells treated with pituitary LH. Both rbbLHβα and rybLHβα preparations contained
less progesterone in the culture supernatant (15.9 ± 13.1 ng/ml and 7.7 ± 7.1 ng/ml,
respectively), with only the rybLHβα protein exhibiting a trend (p < 0.1; Figure 3.4B).
In vivo assay
The relative ovarian ascorbic acid content increased from pre- to post-LH
treatment for each treatment group, although the increase was modest for this assay. The
increase for the vehicle-only treatment (negative control) was 17.6 ± 2.46%. The highest
increase was found in the pituitary ovine LH treatment group (23.4 ± 19.5%) with the
rbbLHβα and the rybLHβα increasing ascorbic acid slightly less (11.3 ± 19.5% and 11.3
± 7.9%, respectively; Figure 3.5).
Discussion
Granulosa cells of ovarian follicles that are greater than 10 mm are post-deviation,
suggesting that the follicle will mature to ovulation. These cells have altered
predominant surface receptor gene expression from FSHR to LHR and rely on LH to
reach full maturity (Adams et al. 1992). Adding a bolus of LH to these cells mimics the
pre-ovulatory LH surge associated with ovulation, altering the cells from estrogen
synthesis to progesterone (Nimz et al. 2010). The CYP19A1 gene, which is associated
with estrogen biosynthesis, would be expected to decrease after a bolus of LH treatment.
In our experiment, we see a slight increase in CYP19A1 transcript level. The decrease in
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A

B

Figure 3.4 Gene expression profile of bovine granulosa cells isolated from follicles >10 mm and cultured in vitro with LH
treatment for one day.
A: Relative fold change of CYP19A1, FSHR, and LHR gene transcripts (GAPDH used as reference gene) after incubation with either
pituitary ovine LH, rbbLHβα, or rybLHβα treatment. The fold changes are given as the mean of three replicates. B: Progesterone content
(ng/ml) of culture supernatant. * Significant difference for treatment vs. control (p < 0.1).
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Figure 3.5 Biological activity assay for bLH –ovarian ascorbic acid depletion assay. Relative ovarian ascorbic acid post-LH treatment
when compared to pre-treatment of peri-mature female rats. Treatments as follows: No LH (vehicle-only control), 50 µunits pituitary
ovine LH, and 20 µg rbbLHβα and rybLHβα. n = 3 for each group.
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FSHR transcript levels after treatment with LH was predicted because the granulosa cells
were obtained from follicles greater than 10 mm which were already predominantly
expressing LHR. The nature of these follicles, combined with the LH treatment, suggests
any residual FSHR expression would be down-regulated. The full effects of cellular
luteinization may not have been realized after one day of incubation with LH treatment.
Complete luteinization of granulosa cells in vitro may take up to 8 days with LH
(Mamluk et al. 1998), suggesting a longer incubation time in this study may have resulted
in further differential expression of FSHR and CYP19A1 gene transcripts.
An increase in LHR transcript level after the addition of LH was a possible
outcome because LH could trigger up-regulation in an autocrine response. However,
after 1 day of LH treatment, LH caused a repression in LHR expression, suggesting an
autocrine down-regulation. The potential down-regulation of LHR is also reflected in the
reduction of progesterone seen in the culture supernatant after 1 day of LH treatment,
which would support the likelihood of successful LH protein receptor activation. Others
have reported a down-regulation of LHR transcript after luteinization of granulosa cells
in vitro with LH (Mamluk et al. 1998), suggesting luteinized granulosa cells (which
become the large luteal cells) do not possess as much LHR transcript and may not be
sensitive to LH.
The pituitary LH caused the greatest LHR transcript repression, with the rbbLHβα
exhibiting the smallest LHR transcript decrease. This difference could be a consequence
of a higher amount of LH activity in the pituitary LH samples. The LH activity in the
crude commercial pituitary LH preparation in units of protein mass is difficult to
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determine given the complexity of the crude material. Therefore it is difficult to compare
the product with the recombinant proteins. A direct comparison of the recombinant
proteins suggest that rybLHβα caused a greater decrease in LHR receptor than the
bacterial protein did, suggesting it may be the more active of the two heterologous
proteins.
The ovarian ascorbic acid depletion assay is the industry standard for determining
the activity of LH preparations. Here, too few animals were used to merit statistical
significance, so all data obtained should be considered preliminary. Every treatment
group resulted in an increase in relative ascorbic acid content from pre- to post-LH
treatment. This was unanticipated because LH has been reported to trigger the oxidation
of ascorbic acid in the rat ovary, resulting in as much as a 46% decrease in ascorbic acid
content three hours post-LH administration (Goldstein and Sturgis 1961). The relative
ascorbic acid content pre- to post-LH treatment increased in the vehicle-only treatment
group, suggesting the vehicle may have caused the increase in ascorbic acid for unknown
reasons. While, both the rbbLHβα and rybLHβα treatments resulted in an overall
increase in relative ascorbic acid content post-LH treatment, the concentrations were less
than the vehicle-only control, suggesting an overall reduction.
The description and use of recombinant bovine LH production in the literature is
limited. Kaetzel et al. (1985) reported in vitro activity through an increase in production
of progesterone after treatment of ovine luteal cells, but did not comment on in vivo
activity. Grinberg et al. (2008) incorporated the carboxy-terminal peptide (CTP) and
compared two subunit fusion orientations (α-CTP-β vs. β-CTP-α), finding the α-CTP-β
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orientation increased progesterone production from rat granulosa cells. The CTP is a
unique ~25 amino acid domain on the placental-derived human chorionic gonadotropin
(another glycoprotein within the same hormone family as LH) β-subunit, coding for four
O-linked glycosylation sites (Pierce and Parsons 1981). The addition of the CTP has
proven to increase biological activity of recombinant gonadotropins, working with the Nlinked glycosylations already present to protect the protein from proteases within the
body (Fares et al. 1992; Lemke et al. 2008; Jennings et al. 2009).
There are a number of other citations reporting recombinant LH use in species
such as fish, horses, and humans. The majority of these recombinant LH preparations
exhibited in vitro activity, but the reports failed to comment on in vivo activity (Gadkari
et al. 2003; Zmora et al. 2007), or the preparations showed an apparent lack of in vivo
activity (Hakola et al. 1997; Galet et al. 2001; Ko et al. 2007).
Conclusions
rybLHβα may be more active than rbbLHβα based on the greater reduction of
LHR gene transcript after one day of incubation in vitro with LH treatment, however
neither recombinant protein appeared to be as active as the pituitary-derived LH, which
could be attributed to the total amount of protein administered. The rat ovarian ascorbic
acid biological assay did not show an overall depletion of ascorbic acid post-LH
treatment as expected, but both the recombinant treatments showed a decrease in ascorbic
acid content when compared to the vehicle-only control group, suggesting any effects
may have been masked by unknown factors.
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CHAPTER FOUR
SUMMARY

Recombinant bFSH and bLH have been produced from both bacteria and yeast
heterologous hosts, with most products being extremely pure (>95%). Bacterial bFSH
showed biological activity using a rat ovarian weight gain assay, whereas the yeast bFSH
activity was not determined from the same assay due to unknown complications.
Recombinant yeast bLH may be more active than recombinant bLH based on the greater
reduction of LH receptor gene transcript observed after incubation in vitro with LH;
however, neither recombinant protein appeared to be as active as the pituitary-derived
LH, which may reflect the consequences of different amounts of total protein
administered.
The production of recombinant gonadotropins has changed human assisted
reproductive technologies, and implementation in the bovine superovulation industry
could have similar positive effects. Recombinant bovine FSH was produced originally
back in the 1980s from a mammalian cell line, but difficulties scaling to commercial
levels as well as complex government approval (in part a consequence of using a
mammalian cell product in mammals, which could lead to disease transmission) hindered
the treatment from gaining popularity. A recombinant preparation can add a level of
safety and consistency to bovine superovulation protocols.
While Chinese hamster ovary cells (typical mammalian recombinant protein
production cell line) have proven to produce active gonadotropins, there is still

97

uncertainty about the potential for the fetal bovine serum used in culture media to
transmit prions and other disease-causing agents. Using a heterologous expression
system that requires no fetal bovine serum would resolve this issue. Lower-order
organisms that can be cultured in the absence of serum (such as bacteria, yeast, or plants)
may not be able to produce gonadotropins that possess important post-translational
modifications found associated with the mammalian product, which may reduce
biological activity. This limitation may be overcome by novel gonadotropin delivery
methods such as a mini-pump or a slow-release implant. Alternatively, the ability to
generate large amounts of recombinant protein may allow users to supply a greater dose
of protein, effectively overcoming half-life concerns.
Finally, implementing recombinant gonadotropins into the cattle industry may
reduce costs associated with these drugs. Currently, FSH is the most expensive part of
the bovine superovulation protocol, mainly because of the price of the product, but also
because of the labor required to administer eight injections of the drug within a span of
four days. Providing a more pure product (recombinant preparations), along with
decreased injection frequency, could benefit the cattle industry substantially.
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APPENDICES
Appendix A
Production of recombinant FSH in a Kluyveromyces lactis heterologous system

Abstract
Production of recombinant bovine FSH was attempted through the use of the
Kluyveromyces lactis yeast expression system. K. lactis is capable of secreting
glycosylated forms of recombinant proteins into culture media, facilitating production
and purification. The bovine FSH gene subunits were cloned into the pKLAC1
expression cassette and GG799 K. lactis cells were transformed. Protein expression was
induced using 2% galactose for 1-4 days at either room temperature or 28oC. The
resulting fused protein was not secreted into the culture media and could only be liberated
from the insoluble fraction of the cell pellet after cell lysis and denaturing purification.
Introduction
Recombinant porcine gonadotropin production in heterologous yeast systems has
been well documented. The majority of gonadotropin research utilizing yeast as a
production method has been performed using the Pichia pastoris yeast expression
system. Since P. pastoris was the traditional system of choice, a novel approach to
bovine FSH production was initially chosen, the Kluyveromyces lactis system. In the K.
lactis system, genes are cloned downstream of the α-mating factor, which directs the
secretion of the nascent protein into the growth media during protein induction. Selection
of positive transformants is achieved by incorporation of a fungal acetamidase gene that
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converts acetamide to ammonia to use as a nitrogen source for growth on nitrogen-free
media (New England Biolabs 2007). The following describes experiments aimed at
assessing the utility of the K. lactis system in heterologous expression of bovine FSH
(bFSH).
Materials and Methods
The bovine FSH gene subunits were PCR amplified from bovine anterior pituitary
cDNA and products ligated into the pKLAC1 expression plasmid using a cloning strategy
designed to generate a fusion protein of an N-terminal 6 histidine (6his) purification tag,
followed by the β-subunit upstream α-subunit. The primers can be found in Table D.1.
The β/α fusion gene was cloned into novel Bgl11 and Sal1 restriction sites found in the
multiple cloning site. The resulting construct was transformed into competent DH5α
bacterial cells for plasmid amplification. The plasmid (1µg) was then linearized using
Sac11 and transformants selected by growth at 30oC for 5-7 days on agar plates
containing 5 mM acetamide. Protein production for selected clones was induced for 1-4
days at room temperature or 30oC using 2% galactose. Cells were harvested by
centrifugation (1500 x g; 10 min; 4oC) and lysed for 3 min using 0.5 mm glass beads
(Model 1107900, BioSpec Products Inc, Bartlesville, OK). Protein was analyzed from
spent culture media as well as induced cell pellet using 12% SDS-PAGE followed by
Coomassie Brilliant Blue staining and western blotting. Blots were blocked for 1 hr in
1% non-fat milk and 1o mouse α-6his antibody (1:2000) or 1o α-ovine FSH (1:250) added
for 1 hr. Primary antibodies were detected with goat-α-mouse (GαM) horseradish
peroxidase (HRP; 1 hr). HRP was visualized using SuperSignal® West Pico
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Chemiluminescent Substrate Kit (Pierce®, Rockford, IL). Denaturing purification was
performed with 8 M urea and purification was performed using nickel affinity
chromatography.
Results
After 1-4 days of protein induction at either room temperature or 30oC,
recombinant yeast bFSHβα (rybFSHβα) protein was not detected in the spent culture
media, and was only detected in the cell pellet fraction (Figure A.1, lanes 1 and 3). After
a large-scale expression (Figure A.2) and further analysis of the cell pellet by denaturing
purification utilizing 8 M urea, the recombinant protein was detectable in the soluble
fraction (Figure A.3), but was refractory to purification by nickel affinity
chromatography.

Figure A.1 Small-scale expression study of rybFSHβα-6his in K. lactis yeast. Protein was
induced with the addition of 2% galactose at either room temperature or 30oC for 1-4 days.
Analysis was performed on small samples of pelleted cells (CP) or spent culture supernatant (CS)
using 1o mouse α-6his (1:2000), 2o GαM HRP (1:5000).
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Figure A.2 Western blot of rybFSHβα-6his protein expression from K. lactis GG799 cells.
Protein expression was induced for 1 day at RT. Lane 1: yeast induction culture cell pellet. Lane
2: yeast induction culture supernatant. Protein detected using 1o α-6his antibody (1:2000) and 2o
GαM HRP (1:5000).

Figure A.3 Western blot detecting rybFSHβα-6his produced from K. lactis after denaturing
purification. Protein expression was induced for 3 days at room temperature and yeast cell pellet
was beaten using 0.5 mm glass beads to facilitate lysis. Lane 1: yeast culture supernatant postinduction. Lane 2: soluble fraction after cell pellet lysis. Lane 3: insoluble fraction after cell pellet
lysis. Protein detected using 1o α-ovine FSH antibody (1:500) and 2o GαM HRP (1:2000).

Discussion
The K. lactis expression cassette was chosen because it was a novel expression
system for bovine gonadotropin production, and for its ability to channel nascent
recombinant proteins through the secretory pathway into the culture media during protein
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induction. After manipulating a multitude of expression procedures (combinations of
size of culture and induction temperature and length), the rybFSHβα was liberated from
the insoluble fraction of the induced cell pellet only after urea denaturation. Denaturation
is not ideal for industrial scale production, so this method of yeast recombinant protein
production was abandoned for the Pichia pastoris expression system, in hopes of
producing a secreted recombinant protein product.

References
New England Biolabs, Inc., 2007. K. lactis protein expression kit: Instruction Manual.
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Appendix B
Optimizing recombinant bovine FSH protein production through manipulation of subunit
orientation

Abstract
In an attempt to optimize protein production from bacterial expression systems,
the order of FSH subunit genes (α first, followed in fusion with β, or with the order
switched) and the addition of a linker sequence between the subunits were considered.
After successful cloning, the FSH expression cassette was transformed into a number of
bacterial strains in order to explore optimized soluble protein expression. None of these
alterations resulted in an efficient method to produce recombinant bacterial-derived
bovine FSH.
Introduction
Protein subunit gene orientation and linking sequence
FSH is produced by mammals as two separate subunits that are non-covalently
associated post-translation (Pierce and Parsons 1981). In initial recombinant protein
production efforts, gonadotropins were produced in this way, as two separate products
that were associated post-production (Kaetzel et al. 1985; Keene et al. 1989). This
method was effective but required multiple production steps. Subsequent research has
proven that FSH can be produced as a single construct, with both subunits being
expressed in tandem (Olijve et al. 1996; D’Antonio et al. 1999). The question then
becomes if a specific subunit orientation in a fusion construct favors greater solubility or
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activity. Further, adequate folding of the tethered protein may be inhibited because of the
physical constraints of the linker. Additionally, there may be a balance between linker
size required to facilitate appropriate flexibility while not being so large as to interfere
with activity. Protein linker sequences have traditionally incorporated neutral amino
acids such as glycine which have a low tendency for forming α-helices or β-sheets and
have been as short as possible. Linking sequences can also incorporate purification tags,
glycosylation sites, or protease sites (Robinson and Sauer 1998, Crasto and Feng 2000).
The following set of experiments was conducted to produce multiple FSH constructs with
varying orientations of subunits and linking sequences.
Protein expression in multiple bacterial strains
In order to optimize soluble protein expression, multiple bacterial host strains
were considered. A summary of the bacterial strains that were used, along with some key
features, can be found in Table B.1. All of these strains were chosen because they
inducibly express T7 RNA polymerase. The Rosetta bacterial strains express extra tRNA
(AGG, AGA, AUA, CUA, CCC, and GGA) that bacteria do not typically harbor at high
concentrations. This can enhance the production of mammalian recombinant proteins.
The RosettaGami strain is engineered to increase the formation of disulfide bonds to aid
in protein folding and stability. The pLysS plasmid found in the RosettaBlue and II
strains expresses the T7 lysozyme, a protein which binds and represses T7 RNA
polymerase until expression is induced to prevent leaky expression of potentially toxic
heterologous products (Zhang and Studier 1997).
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Table B.1 Bacterial strains used to explore recombinant bovine FSH induction.

Bacterial Strain

↑TE*

NovaBlue(DE3)

√

RosettaBlue(DE3)

√

T7 lysozyme

Extra tRNA

√

√

√

√

RosettaII(DE3)

√

RosettaGami(DE3)

↑Disulfide
bonds

√

*Abbreviations: TE: transformation efficiency

Materials and Methods
Bovine FSH (bFSH) α- and β-subunit genes were PCR amplified from bovine
anterior pituitary cDNA and novel restriction sites added as a result (see Tables D.2 and
D.3 for primer sequences). After production, the two purified subunit genes were ligated
together in one of two orientations: β-subunit upstream of α-subunit, or vice versa (Figure
B.1), and the full length fusion amplified by PCR using flanking primers (see Figure B.1,
rows A and B, for primer orientations and Tables D.2 and D.3 for primer sequences).
Alternatively, a triple myc tag (three myc tags in fusion, 5’
GAACAAAAACTCATCTCAGAAGAGGATCTG3 3’) was ligated between the two
subunits, again in either β/α or α/β configuration (Figure B.1, rows C and D, and Table
D.4 for primer sequences). These constructs were transformed into the shuttle vector
pGEMEZ-T for gene amplification. Subsequently, the bFSH fusion gene was digested
from the shuttle vector and ligated into the vector pGEX4T-1 and sequenced. Plasmids
were transformed by electroporation (ECM830, BTX, Holliston, MA) into either
BL21(DE3) bacteria, or one of the aforementioned alternative bacterial cell lines (Table
B.1). Cultures were grown to OD600 of 0.6 in terrific broth media (1% tryptone, 2.5%
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Figure B.1 Pictorial representation of various expression plasmids produced in order to
optimize bFSH subunit orientation, and to insert a linking sequence between the two
subunits.

yeast extract, 0.4% glycerol, 17 µM KH2PO4, 72 µM K2HPO4) at 37oC and protein
expression induced by addition of 250 µM IPTG at either room temperature or 37oC for
either 3 h or overnight. bFSH was purified using affinity chromatography, taking
advantage of the GST tag provided by the pGEX4T-1 vector engineered at the Nterminus of the protein. Purification fractions and induced cell pellets were analyzed by
12% SDS-PAGE stained with Coomassie Brilliant Blue and western blotting. For
westerns, protein was transferred from acrylamide gels to nitrocellulose at 16 V for 40
min (TransBlot SD Semi Dry Transfer Cell, BioRad, Hercules, CA). Blots were blocked
(1% non-fat milk) for 1 hr, and 1o α-GST-biotin (1:2000) or 1o α-ovine FSH (1:250)
antibodies were incubated for 1 hr at RT, followed by 2o α-biotin horseradish peroxidase
(HRP; 1:5000) incubated for 1 hr at RT. HRP was visualized using SuperSignal® West
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Pico Chemiluminescent Substrate Kit (Pierce®, Rockford, IL). Protein concentration
was determined using a BCA Assay kit (Pierce®, Rockford, IL).
Results and Discussion
Subunit orientation
Following the identification of positive clones of both bFSH subunit orientation
plasmids, protein production was initiated. More information on bFSHβα production can
be found in Chapter 2. Briefly, bFSHβα-GST protein was produced from BL21(DE3)
bacterial cells, but a frame-shift mutation in the expression plasmid caused an excess of
free GST to be produced rather than the GST-fusion protein. Re-cloning efforts were
unsuccessful. bFSHαβ-GST protein was isolated from the soluble fraction after bacterial
lysis (Figure B.2), and was concentrated at 825 µg/ml (purity estimated at ~80%).

Figure B.2 Wash purification fractions of rbbFSHαβ. A: α-GST antibody (1:2000). B: αovine FSH antibody (1:500). Protein concentration was assessed at 825 µg/ml and purity
estimated at 80%.
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Linker sequence introduction
Initial attempts at cloning a myc3 linker between the subunits employed a myc
oligomer with Kpn1 sites at both termini. This approach was designed to clone the myc3
tag using the Kpn1 site employed in the original fusion ligation (β/α or α/β). Introduction
of the myc3 tag using this approach worked, but all myc inserts were in the wrong
orientation, introducing a stop codon where the myc3 tag should have been. A second
cloning strategy was used, employing directional cloning using two different restriction
sites for the 5’ and 3’ ends of the myc3 tag. This strategy failed for reasons that are not
clear, with the sequencing of every construct being negative.
Alternative bacterial strains for bFSHβα production
Expression of bFSHβα was induced in five bacterial strains, the first being
BL21(DE3). Soluble protein was not attained from this cell line, so the other four cell
lines were utilized. Hourly expression samples from small-scale induction cultures using
each bacterial strain can be found in Figure B.3. The two strains that yielded the most
protein (NovaBlue and Rosetta II, Figure B.3, rows A and C) were then induced in larger
cultures, and affinity chromatography utilizing the N-terminus GST tag was performed.
The resulting protein did not bind the GST column and was found in the flow-through
and early wash steps (Figure B.4). Re-sequencing revealed a frame-shift in the GST
gene, resulting in the loss of a functional protein, explaining loss of binding. At this
point, re-cloning would be necessary and expression studies would follow to determine
conclusively the value of subunit gene orientation and linker use.
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Figure B.3 Expression profiles of rbbFSHβα in 4 bacterial strains. Protein expression was
induced addition of 250 µM IPTG and samples of uninduced and induced cultures were taken
every hour for 3 hours. Protein analysis was performed using Western blotting: 1o α-GST
antibody (1:2000) and 2o α -biotin (1:5000). A. NovaBlue(DE3). B. RosettaBlue(DE)3pLysS. C.
RosettaII(DE3)pLysS. D. RosettaGami(DE3)pLacI.

Figure B.4 Large-scale expression of rbbFSHβα from NovaBlueDE3 bacterial cells. Protein
was induced using 250 µM IPTG for 3 hours at 37oC. Protein analysis was performed using
Western blotting: α-GST antibody (1:2000) and 2o α -biotin (1:5000). Protein was seen in flow
through (FT) fractions, all washes (W1-3) and the first two elution fractions (E1-2), suggesting
protein did not bind GST purification column.
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Conclusions
The production of β/α subunit orientation protein was unsuccessful due to a
frame-shift mutation. Protein in the α/β subunit orientation was produced from bacterial
cells, but purification efforts were not pursued. Finally, any attempts to insert a linker
sequence between the two subunits were unsuccessful.
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Appendix C
Purification and characterization of recombinant human glucokinase

Abstract
Glucokinase (GK) is the key glucose sensor in mammals, metabolizing glucose
into glucose-6-phosphate. Mutation or incorrect splicing of the human GK (hGK) gene
can lead to multiple forms of mature-onset of diabetes in the young (MODY). Activators
of the GK enzyme would potentially be useful as a drug therapy for MODY, type II
diabetes, and glucose homeostasis. Here, we describe the expression and purification of
recombinant hGK for use in screens aimed at identifying both inhibitors and activators of
this enzyme. The hGK gene was cloned from cDNA into the pQE30 expression plasmid
and transformed into M15(pREP) E. coli bacterial cells for induction of protein
expression. A battery of assays was performed with purified hGK to test for enzyme
activity, optimal storage conditions, and use of phosphoryl donors. Finally, compounds
from a screen for inhibitors of a related enzyme, Trypanosoma brucei hexokinase
(TbHK), were tested against hGK for inhibition and activation.
Introduction
GK (also known as hexokinase IV) is one of four hexokinases found in mammals.
GK is the rate limiting enzyme for the phosphorylation of glucose to glucose-6phosphate, which is the first step in glycolysis. hGK is expressed in liver, brain, gut
endothelium, and pancreatic β cells, with the latter being the location of insulin regulation
associated with glucose uptake from the circulation, facilitated by GLUT2 transporter
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(Osbak et al. 2009; Pal 2009). GK is regulated in the pancreas β cells by the availability
of its substrate, glucose, and controls the amount of glucose that enters into glycolysis
(Giuffrida and Reis 2005). As a consequence of mutation, some of which leads to
generation of splice variants (hGK is encoded in 12 exons), a number of hyper- and hypoglycemic disorders can be attributed to hGK (Osbak et al. 2009).
MODY is a disorder caused by mutation of the hGK gene which results in
pancreatic β cell disfunction (Osbak et al. 2009; Colom and Corcoy 2010). MODY
phenotypes are based on type and frequency of mutation of hGK gene and HNF
(hepatocyte nuclear factor) genes, which play a fundamental role in the function of
pancreatic β cells (Giuffrida and Reis 2005). In milder forms (MODY2), less insulin (up
to 60% reduction) is secreted as a result of inappropriate glucose sensing in the pancreas,
as well as a hepatic glucose phosphorylation deficiency (Velho et al. 1996). The mildform disorder typically presents with mild fasting hyperglycemia and can usually be
controlled by diet alone. More severe forms (MODY3) usually require insulin
replacement therapy or oral hyperglycemic agents, and those affected may be at risk for
vascular disease (Giuffrida and Reis 2005; Osbak et al. 2009). Activators of hGK could
be an ideal treatment for some types of MODY in efforts to increase insulin secretion
(Osbak et al. 2009).
hGK activators may also assist in control of type II diabetes, a disorder noted by a
lack of ability to make or utilize insulin in the pancreatic β cells in obese adults. This
leaves excess glucose and potentially excess insulin in the circulatory system, causing
problems such as lipid buildup, renal failure, and vascular neuropathy. Activation of
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hGK may assist by stimulating the usage of glucose in the pancreas or liver. Glucose
activators may also be useful for neurons in the brain that are responsible for sensing
changes in glucose levels within the body and maintaining glucose homeostasis (Pal
2009). Here, we have screened a panel of compounds known to bind to hexokinases
(identified in a screen for inhibitors of TbHK) for activators and inhibitors of hGK.
Materials and Methods
Reagents
Quercetin dehydrate (QCN; 3,3’,4’,5,7-pentahydroxyflavone) was purchased from
Spectrum Chemical Manufacturing Corporation (Gardena, CA). Lonidamine (LND; 1(2,4-dichlorobenzyl)-1,H-indazol-3-carboxylic acid) was purchased from Sigma-Aldrich
(St. Louis, MO). All HTS compounds were supplied by University of Kansas
Specialized Chemistry Center (Lawrence, KS).
Expression of hGK
hGK cDNA was purchased from Open Biosystems (Huntsville, AL). PCR was
used (Forward primer 5’GATC GGA TCC CTG GAC GAC AGA GCC 3’; Reverse
primer 5’ GATC AAG CTT CTG GCC CAG CAT ACA GGC 3’) to amplify the ORF,
and cloned into pQE30 using BamH1 and Hind111 restriction sites engineered into the
primers for cloning. This construct generates an N-terminal RGS(His)6 tag for affinity
purification.
Plasmid was then transformed into M15(pREP) E. coli cells for protein
expression. Briefly, a 1 L terrific broth culture of M15(pREP) harboring pQE30hGK was
grown to an OD600 of 0.6 and protein expression induced for 4 hours at 37oC by addition
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of 1 mM IPTG. Bacteria were collected by centrifugation (10,000 x g, 30 min, 4oC) and
the resulting cell pellet lysed in 1% tosyl-L-lysine chloromethyl ketone (50 mg/mL), 2
mg/mL lysozyme, 0.1% Triton X-100, and 10 mM glucose. The resulting lysate was then
centrifuged (10,000 x g, 30 min, 4oC) and protein from the soluble fraction purified using
nickel affinity chromatography (Ni-NTA Agarose, Qiagen) as directed by the
manufacturer. Purified hGK was analyzed on 15% SDS-PAGE and Coomassie staining
or western immunoblotting using an α-RGS(His)6 antibody and chemiluminesence.
Protein was stored at -80oC in 20% glycerol.
Enzyme assays
Enzyme activity was determined using a previously described HK assay (Misset
et al. 1984; Morris et al. 2002). Briefly, the assay employed glucose-6-phosphate
dehydrogenase (0.1 unit/assay, EMD Biosciences, Inc, San Diego, CA) to convert
glucose-6-phosphate (G6-P) generated by hGK to 6-phoshogluconate with coincident
reduction of NADP to NADPH. Reagent final concentrations in the 200 µl reactions
were: 50 mM triethanolamine (TEA), 33 mM MgCL2, 20 mM glucose, 5.25 mM ATP,
and 0.75 mM NADP. Assays were performed in a 96-well microtiter plate and read in a
GENios spectrophotometer (Phenix Research Products, Hayward, CA).
Inhibition/Activation assays were performed by the addition of various compounds to the
aforementioned HK assay with a 10 minute incubation of hGK and inhibitor prior to
addition of remaining assay components.
Results
Enzyme purification
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hGK was purified from the soluble fraction of the bacterial cells using nickel
affinity purification. Protein expression was assessed by SDS-PAGE and western
blotting (Figure C.1). hGK was identified as a 55 kDa band by Coomassie staining
consistent with its predicted size and protein purity was estimated at >99%. Western
blotting confirmed the species to be a RGS-6His-bearing polypeptide. Elution fractions
from the purification were pooled and stability was tested at various temperatures with
and without 20% glycerol. Optimal stability was found at -80oC with 20% glycerol.
After 1 month, 76% of the initial enzyme activity remained (data not shown). Using
native gel electrophoresis, hGK was found to be a monomer unlike the Trypanosoma
brucei hexokinases which form a hexamer (Chambers et al. 2008).

Figure C.1 Recombinant hGK protein induced from E. coli bacterial cells overnight at RT.
Cell pellet was lysed and protein was purified from soluble fraction using nickel affinity
chromatography. A: Coomassie stain of purified fraction. B: Western blot of purified purification
fraction using 1o α-6his (1:2000), 2o GαM HRP (1:5000).
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Enzyme kinetics
After positive identification, the protein was analyzed for its enzymatic activity by
enzyme coupled HK activity assay. hGK was found to have a specific activity of 872.6
mmol min-1 mg-1, with Km of 9.36 mM for ATP and 0.258 mM for glucose.
Phosphoryl Donors
To further interrogate the enzyme activity, alternative phosphoryl donors were
considered, including ADP, AMP, and ITP. None of these supported enzyme activity (as
detected by glucose-6-phosphate production).
Enzyme assay optimization
HKs from other systems have been reported to be sensitive to pH, but protected
from pH-based inactivity by the addition of glyerol-3-phosphate (unpublished
observation). Under acidic conditions less than pH 6.0, hGK enzyme is inactivated. The
addition of glycerol-3-phosphate (20 mM) restores detectable activity. Notably,
inactivation is the result of excess ATP, as reduction of ATP under acidic (pH 6.0)
conditions limits inactivation (Figure C.2). These observations suggest that hGK, like the
TbHK, has an allosteric site for nucleotide binding that is exposed under acidic
conditions.
Inhibition/Activation Assays
A number of known and potential inhibitors of hexokinase were added to the HK
assay to assess their effects on hGK. LND and fumurate, both reported to inhibit TbHK,
were modest inhibitors (IC50 = 538 µM and 66% at 10 µM, respectively) while QCN was
more potent with an IC50 = 8 µM. A number of other compounds were analyzed and
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Figure C.2 Human GK activity under acidic conditions. Activity of hGK was assayed under
acidic conditions (pH 6.0) and in the presence or absence of glycerol-3-phosphate, and with either
5 mM or 0.5 mM ATP. Values are compared to hGK under normal physiologic conditions (pH
7.4), which is set to 100% activity.

found to have little inhibitory effects (at 1 mM), including myristate, butyrate, succinate,
and malate. hGK was also used as part of a collaborative effort. In a computer screen of
T. brucei HK inhibitors, a number of potent hGK inhibitors were identified including
SID87326000 and SID85786737 (91.5 ± 1.9% and 56.1 ± 0.66% inhibition at 10 µM,
respectively). Because these are single concentration points, structure activity
relationships (SAR) are difficult to resolve. Activators, including SID97302142 and
SID97302151 (27.0 ± 2.8% and 23.1 ± 5.6% activation at 10 µM, respectively) were also
identified. The results of these inhibition assays are found in Table C.1.
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Table C.1 hGK activity in the presence of potential inhibitor or activator compounds.
% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

1

17387000

30.8 ± 9.0

2

85285421

39.6 ± 1.9

3

85285422

50.1 ± 3.0

4

85285424

Structure

85742030

28.2 ± 9.8

6

85742031

8.84 ± 4.49

7

85742032

28.9 ± 6.9

85742033

Entry

9

85742034

0.0

10

85747718

35.6 ± 8.7

11

85752767

++

12

85752848

37.8 ± 3.4

13

85786735

48.8 ± 6.0

14

85786736

56.2 ± 0.88

15

85786737

56.1 ± 0.66

16

85786738

55.6 ± 3.8

Structure

37.2 ± 2.6

5

8

% hGK
Inhibition
(10 µM)

PubChem
SID

34.9 ± 2.0
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% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

17

85786739

55.0 ± 1.2

18

85786740

49.9 ± 2.5

19

Structure

87225565

Entry

25

87325999

41.2 ± 6.8

26

87326000

65.6 ± 5.4

27

87326001

91.5 ± 1.9

28

87326002

51.9 ± 14.6

29

87326003

45.7 ± 13.3

30

87350305

0.0

31

87350306

0.0

Structure

+

20

87225566

0.0

21

87225567

11.37 ± 9.6

22

87225568

+

23

87225569

0.0
O
F

24

% hGK
Inhibition
(10 µM)

PubChem
SID

87225570

0.0

N
S
Cl
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Entry

PubChem
SID

32

87350307

33

87350308

Structure

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

39

87550700

% hGK
Inhibition
(10 µM)

Structure

13.6 ± 7.8
0.0

22.1 ± 4.9
O

N

40
34

87350309

87550701

0.0

S

0.0

NH
O
O

35

87350310

33.8 ± 1.1

36

87350311

36.2 ± 4.4

37

87350312

54.0 ± 11.6

38

87550699

0.0
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41

87550702

0.0

42

87550703

0.0

43

87550704

0.0

44

87550705

0.0

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

45

90944616

0.0

46

90944617

16.9 ± 14.3

47

90944618

++

48

49

90944619

90944620

Structure

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

52

90944623

0.0

53

92126107

38.3 ± 6.65

54

92126109

32.9 ± 15.0

55

92126110

33.8 ± 8.23

56

92126111

23.8 ± 7.19

57

92126112

22.2 ± 17.6

58

92126113

14.3 ± 3.14

59

92126114

0.0

Structure

+

+

50

90944621

++

51

90944622

++
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Entry

PubChem
SID

60

92126115

61

62

63

% hGK
Inhibition
(10 µM)

Entry

40.1± 10.5

68

92708921

++

92708914

26.1 ± 1.54

69

92708922

0.0

92708915

14.1 ± 9.5

70

92708923

0.0

71

92708977

0.0

72

93575714

0.0

73

93575715

16.7± 2.3

74

93575717

0.0

75

93575720

0.0

92708916

92708917

+

65

92708918

+

67

92708919

92708920

Structure

8.01 ± 3.9

64

66

% hGK
Inhibition
(10 µM)

PubChem
SID

Structure

++

32.2 ± 24.3
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Entry

PubChem
SID

76

93575721

77

78

% hGK
Inhibition
(10 µM)

Entry

10.9± 6.5

84

93575729

0.0

93575722

0.0

85

93618290

+

93575723

0.0
86

93618291

7.02 ± 4.5

87

93618292

0.0

88

93618293

0.0

89

93618294

0.0

90

93618295

++

79

93575724

38.4± 0.59

80

93575725

0.0

81

93575726

0.0

82

93575727
(24797131)

83

% hGK
Inhibition
(10 µM)

PubChem
SID

Structure

93575728

Structure

9.26 ± 3.5

0.0
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Entry

PubChem
SID

91

93618296

92

93618297

Structure

% hGK
Inhibition
(10 µM)
NS

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

98

93575716

30.6 ± 7.1

99

93575718

++

100

93575719

10.29 ± 2.6

101

96022034

30.3 ± 8.1

102

96022035

11.1 ± 8.5

103

96022036

18.2 ± 5.5

104

96022037

0.0

Structure

0.0

93

93618298

20.5 ± 14.9

94

93618299

0.0

95

93618300

24.38 ± 4.9

96

93618301

0.0

97

93618302

22.1 ± 8.1
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Entry

PubChem
SID

105

96022038

106

107

96022039

96022040

Structure

% hGK
Inhibition
(10 µM)

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

111

96022044

14.5 ± 3.1

112

96022045

0.0

113

97302133

++

114

97302134

++

115

97302135

++

Structure

++

0.0

0.0

108

96022041

+

109

96022042

+

110

96022043

0.0

127

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

116

97302136

0.0

117

97302137

+

118

97302138

Structure

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

123

97302144

0.0

124

97302145

0.0

125

97302146

++

126

97302147

+

127

97302148

++

128

97302149

+

Structure

++

119

97302139

+

120

97302141

++

121

97302142

+++

122

97302143

0.0

128

Entry

PubChem
SID

129

97302150

130

131

132

133

134

97302151

97302152

97302153

97302154

96022041

Structure

% hGK
Inhibition
(10 µM)
++

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

135

97302155

5.21 ± 3.8

136

99222681

0.0

137

99222682
and
99344412

++

138

99222683

13.1 ± 9.7

139

99222684

+

140

99222685

+

141

99222686

+

142

99222687

15.8 ± 8.2

Structure

+++

++

++

0.0

+

129

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

143

99222688

+

144

99222689

+++

145

99222690

0.0

146

147

148

149

99222691

99222692

99222693

99222694

Structure

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

150

99222695

++

151

99222696

23.1 ± 8.3

152

99234241

+

153

99234242

16.8 ± 3.9

154

99234243

+

155

99234244

+++

156

99234245

+

157

99234246

++

Structure

++

++

++

++
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Entry

PubChem
SID

158

99234247

159

99234248

Structure

% hGK
Inhibition
(10 µM)
+

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

166

99245521

++

167

99245522

11.5 ± 6.3

168

99245523

12.2 ± 4.0

169

99245524

27.6 ± 7.2

170

99245525

12.5 ± 5.5

171

99245526

+

172

99245527
and
99344410

13.5 ± 10.0

173

99344409

+

Structure

+++

160

99234249

+++

161

99234250

+

162

99234251

14.9 ± 8.9

163

99234262

30.3 ± 13.4

164

99234263

0.0

165

99234264

19.5 ± 8.4

131

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

174

99344411

30.1 ± 6.9

175

99344413

17.9 ± 7.5

Structure

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

181

99380766

22.3 ± 6.4

182

99380767

26.2 ± 4.8

Structure

I

176

99344414

21.1 ± 8.4

183

99380768

H
N

I

Cl

Cl

24.3 ± 1.2

OH O
CN

177

178

179

180

99344415

99344416

99344417

99380765

26.0 ± 8.3
184

99380769

32.1 ± 7.8

185

99380770

25.9 ± 7.8

186

99380771

0.0

22.9 ± 6.6

35.4 ± 8.0

17.6 ± 3.9

132

Entry

PubChem
SID

% hGK
Inhibition
(10 µM)

Structure

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

193

99437308

++

194

99460890

0.0

195

99460891

IC50 = 2.2±
0.5 µM

196

99437306

IC50 = 48.3
± 6.9 µM

Structure

Cl
O

187

99380772
OH

188

189

190

99380773

99437303

99437304

22.2 ± 0.62

N
H
OMe

28.4 ± 5.3

9.2 ± 0.61

10.6 ± 7.8

191

99437306

11.9 ± 7.2

192

99437307

+

133

Entry

PubChem
SID

197

99460892

Structure

% hGK
Inhibition
(10 µM)

% hGK
Inhibition
(10 µM)

Entry

PubChem
SID

198

99460893

0.0

199

103023816

0.0

Structure

0.0

*Abbreviations: NS = not soluble; IC50 = Concentration
required for 50% inhibition; + = 0-10.9 % activation; ++ =
11-20.9% activation; +++ = >21% activation.
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Discussion
A number of compounds found in the high throughput screen were found to
activate hGK. As previously mentioned, drug therapies aimed at activating hGK may be
useful in multiple diabetes disorders, including MODY and type II diabetes. Small
molecules deemed effective at activating hGK have been previously discovered, and
trials in rats have shown that these molecules are able to reduce circulatory glucose levels
and increase insulin release. Human pharmacological studies with these molecules have
mirrored these results (Matschinsky and Porte 2010).
Alongside the discovered activators, a number of compounds had no consequence
on the activity of hGK. This is important because the intent of the high throughput
screen was to identify potential inhibitors of T. brucei hexokinase. To develop a drug
target against trypanosomiasis (or African sleeping sickness, prevalent in Sub-Saharan
Africa), candidate compounds should inhibit the trypanosome hexokinase while not
impacting the activity of the hGK enzyme. Efforts are still underway to discover the
ideal chemistry for this drug target.
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Appendix D
Oligonucleotide primer sequences for gene amplification and qRT-PCR

Table D.1 Oligonucleotide primer sequences for amplification of bovine FSHβα into K. lactis
yeast protein expression cassette, pKLAC1.

Primer Sequence
bFSHβ
5’ GATCAGATCTAGAGGATCGCATCACCATCACCATCACAAGTCTGTCCAGTTC 3’
For
Rev 5’ GATCGGTACCTTCTTTGATTTCCCTGAAGG 3’
bFSHα
5’ GATCGAATTCGATTACTACAGAAAATATGC 3’
For
Rev 5’ GATCGTCGACTTAGGATTTGTGATAATAACAAG 3’

Table D.2 Oligonucleotide primer sequences for amplification of bovine FSH β subunit, LH
β subunit, and the common α subunit in E. coli bacterial protein expression cassette,
pGEX4T-1.

Primer Sequence
bFSHβ For 5’ GATCGGATCCAAGTCTGTCCAGTTC 3’
Rev 5’ GATCGGTACCTTCTTTGATTTCCCTGAAGG 3’
bLHβ For 5’ GATCGGATCCGAGATGTTCCAGGGAC 3’
Rev 5’ GATCGGTACCGAGGAAGAGGATGTC 3’
α-subunit For 5’ GATCGAATTCGATTACTACAGAAAATATGC 3’
Rev 5’ GATCCTCGAGGGATTTGTGATAATAACAAG 3’
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Table D.3 Oligonucleotide primer sequences for amplification of bovine FSHαβ in E. coli
bacterial expression cassette, pGEX4T-1.

Primer Sequence
bFSHα For 5’ GATCGGATCCGATTACTACAGAAAATATGC 3’
Rev 5’ GATCGGTACCGGATTTGTGATAATAACAAG 3’
bFSHβ For 5’ GATCGGTACCAAGTCTGTCCAGTTCTG 3’
Rev 5’ GATCCTCGAGTTCTTTGATTTCCCTGAAGG 3’

Table D.4 Oligonucleotide primer sequences for triple myc tag (linker sequence) insertion
between bovine FSH subunits.

Primer Sequence
Myc3 For 5’ GATCGGTACCGAGCAAAAGCTCATTTC 3’
Rev 5’ GATCGGTACCAAGATCCTCCTCGGA 3’

Table D.5 Oligonucleotide primer sequences for amplification of bovine FSH β subunit, LH
β subunit, and the common α subunit in P. pastoris yeast protein expression cassette,
pPICZαA.

Primer Sequence
bFSHβ For 5’ GATCGAATTCAAGTCTGTCCAGTTCTGTTTC 3’
Rev 5’ GATCGGTACCTTCTTTGATTTCCCTGAAGG 3’
bLHβ For 5’ GATCGAATTCGAGATGTTCCAGGGAC 3’
Rev 5’ GATCGGTACCGAGGAAGAGGATGTC 3’
α-subunit For 5’ GATCGGTACCGATTACTACAGAAAATATGC 3’
Rev 5’ GATCCCGCGGGGATTTGTGATAATAACAAG 3’

139

Table D.6 Oligonucleotide primer sequences for qRT-PCR.

Primer

Sequence

GAPDH For 5’ AGCGAGATCCTGCCAACATCAAG 3’
Rev 5’ GCAGGAGGCATTGCTGACAATCT 3’
CYP19A1 For 5’ GAAGTGCTGAACCCAAGGCATTAC 3’
Rev 5’ AATGAGGGGCCCAATTCCCAGA 3’
FHSR For 5’ TCACCAAGCTTCGAGTCATCCCAA 3’
Rev 5’ TCTGGAAGGCATCAGGGTCGATGTA 3’
LHR For 5’ GCATCCACAAGCTTCCAGATGTTACGA 3’
Rev 5’ GGGAAATCAGCGTTGTCCCATTGA 3’
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Size
Accession no.
(bp)
221 AJ000039
171

Z32741

189

NM_174061

204

NM_174381

